Document:

Exhibit 10.1

Table of Contents

 Exhibit 10.1 
 ASSET PURCHASE AGREEMENT 
 between 
 CELSION CORPORATION 
 and 
 BOSTON SCIENTIFIC CORPORATION 
 Dated as of 
 April 17, 2007 

Table of Contents

 
TABLE OF CONTENTS 
  

			
	 	  	Page
	
ARTICLE I DEFINITIONS 	  	
		
	 SECTION 1.01
Certain Defined Terms 
	  	1
		
	 SECTION 1.02
Definitions 
	  	9
		
	 SECTION 1.03
Interpretation and Rules of Construction 
	  	9
		
	
ARTICLE II PURCHASE AND SALE 	  	
		
	 SECTION 2.01
Purchase and Sale of BPH Assets 
	  	10
		
	 SECTION 2.02
Assumption and Exclusion of Liabilities 
	  	12
		
	 SECTION 2.03
Purchase Price; Allocation of Purchase Price 
	  	14
		
	 SECTION 2.04
Closing 
	  	14
		
	 SECTION 2.05
Closing Deliveries by the Seller 
	  	14
		
	 SECTION 2.06
Closing Deliveries by the Purchaser 
	  	15
		
	 SECTION 2.07
Second Payment 
	  	15
		
	 SECTION 2.08
Third Payment 
	  	15
		
	 SECTION 2.09
Release of Excess Deductions 
	  	15
		
	
ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE SELLER 	  	
		
	 SECTION 3.01
Organization, Authority and Qualification of the Seller 
	  	16
		
	 SECTION 3.02
No Conflict 
	  	17
		
	 SECTION 3.03
Governmental Consents and Approvals 
	  	18
		
	 SECTION 3.04
Financial Information; Books and Records 
	  	18
		
	 SECTION 3.05
Absence of Undisclosed Liabilities 
	  	18
		
	 SECTION 3.06
Inventories 
	  	18
		
	 SECTION 3.07
Absence of Certain Changes, Events and Conditions 
	  	19
		
	 SECTION 3.08
Litigation 
	  	20

  

 i 

Table of Contents

			
	 SECTION 3.09
Compliance with Laws 
	  	21
		
	 SECTION 3.10
Product Approvals 
	  	21
		
	 SECTION 3.11
Environmental Permits and Related Matters 
	  	22
		
	 SECTION 3.12
BPH Material Contracts 
	  	22
		
	 SECTION 3.13
Intellectual Property 
	  	24
		
	 SECTION 3.14
Real Property 
	  	25
		
	 SECTION 3.15
Tangible Personal Property 
	  	26
		
	 SECTION 3.16
BPH Assets 
	  	26
		
	 SECTION 3.17
Customers 
	  	26
		
	 SECTION 3.18
Suppliers 
	  	27
		
	 SECTION 3.19
Taxes 
	  	27
		
	 SECTION 3.20
Insurance 
	  	27
		
	 SECTION 3.21
Full Disclosure 
	  	27
		
	 SECTION 3.22
Brokers 
	  	28
		
	
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE PURCHASER 	  	
		
	 SECTION 4.01
Organization and Authority of the Purchaser 
	  	28
		
	 SECTION 4.02
No Conflict 
	  	28
		
	 SECTION 4.03
Governmental Consents and Approvals 
	  	29
		
	 SECTION 4.04
Litigation 
	  	29
		
	 SECTION 4.05
Brokers 
	  	29
		
	
ARTICLE V ADDITIONAL AGREEMENTS 	  	
		
	 SECTION 5.01
Conduct of BPH Business Prior to the Closing 
	  	29
		
	 SECTION 5.02
Access to Information 
	  	30
		
	 SECTION 5.03
Confidentiality 
	  	31
		
	 SECTION 5.04
Regulatory and Other Authorizations; Notices and Consents 
	  	31

  

 ii 

Table of Contents

			
	 SECTION 5.05
Notice of Developments 
	  	32
		
	 SECTION 5.06
Non-Competition 
	  	32
		
	 SECTION 5.07
Excluded Liabilities 
	  	33
		
	 SECTION 5.08
Bulk Transfer Laws 
	  	33
		
	 SECTION 5.09
Transition Services 
	  	33
		
	 SECTION 5.10
Public Announcements 
	  	34
		
	 SECTION 5.11
License 
	  	34
		
	 SECTION 5.12
Stockholder Meeting; Proxy Materials 
	  	34
		
	
ARTICLE VI CONDITIONS TO CLOSING 	  	
		
	 SECTION 6.01
Mutual Conditions to the Closing 
	  	35
		
	 SECTION 6.02
Conditions to Obligations of the Seller 
	  	35
		
	 SECTION 6.03
Conditions to Obligations of the Purchaser 
	  	36
		
	
ARTICLE VII INDEMNIFICATION 	  	
		
	 SECTION 7.01
Survival of Representations and Warranties 
	  	37
		
	 SECTION 7.02
Indemnification by the Seller 
	  	37
		
	 SECTION 7.03
Indemnification by the Purchaser 
	  	38
		
	 SECTION 7.04
Enforcing Claims Under Indemnity 
	  	38
		
	 SECTION 7.05
Limits on Indemnification 
	  	40
		
	 SECTION 7.06
Treatment of Indemnity Payments 
	  	40
		
	 SECTION 7.07
Set-off Rights 
	  	40
		
	
ARTICLE VIII TERMINATION 	  	
		
	 SECTION 8.01
Termination 
	  	40
		
	 SECTION 8.02
Effect of Termination 
	  	41
		
	
ARTICLE IX MISCELLANEOUS 	  	
		
	 SECTION 9.01
Expenses; Transfer Taxes 
	  	42

  

 iii 

Table of Contents

			
	 SECTION 9.02
Notices 
	  	42
		
	 SECTION 9.03
Headings 
	  	43
		
	 SECTION 9.04
Severability 
	  	43
		
	 SECTION 9.05
Entire Agreement 
	  	43
		
	 SECTION 9.06
Further Action 
	  	43
		
	 SECTION 9.07
Assignment 
	  	44
		
	 SECTION 9.08
Amendment 
	  	44
		
	 SECTION 9.09
Governing Law and Venue 
	  	44
		
	 SECTION 9.10
Waiver 
	  	44
		
	 SECTION 9.11
No Third Party Beneficiaries 
	  	44
		
	 SECTION 9.12
Agreement 
	  	44
		
	 SECTION 9.13
WAIVER OF JURY TRIAL 
	  	44

  

 iv 

Table of Contents

			
	EXHIBITS	 	
		
	1.01(b)	 	Forms of Assignment of Intellectual Property
		
	1.01(c)	 	Form of Assumption Agreement
		
	1.01(d)	 	Form of Bill of Sale and Assignment
		
	2.10	 	Form of Purchaser Amounts Note
		
	5.09	 	Form of Transition Services Agreement

  

 v 

Table of Contents

 PURCHASE DISCLOSURE SCHEDULE 
 The Purchase Disclosure Schedule shall include the following Sections: 
  

			
	3.02	 	No Conflict
		
	3.03	 	Governmental Consents and Approvals
		
	3.05	 	Undisclosed Liabilities
		
	3.06	 	Inventories
		
	3.07	 	Absence of Certain Changes, Events and Conditions
		
	3.08	 	Litigation
		
	3.09(b)	 	Governmental Orders
		
	3.10(a)	 	Product Approvals
		
	3.10(j)	 	Products in Development
		
	3.11(a)	 	Environmental Permits and Related Matters
		
	3.12(a)	 	BPH Material Contracts
		
	3.12(b)	 	Validity of BPH Material Contracts
		
	3.12(c)	 	Third Party Default under BPH Material Contracts
		
	3.13(a)	 	Intellectual Property
		
	3.13(b)	 	Infringement of Intellectual Property
		
	3.13(c)	 	Rights to Intellectual Property
		
	3.13(d)	 	Restrictions on Intellectual Property
		
	3.13(e)	 	Intellectual Property Material to the Conduct of BPH Business
		
	3.13(f)	 	Intellectual Property Litigation
		
	3.13(g)	 	Third Party Infringement
		
	3.13(h)	 	Confidential BPH Intellectual Property
		
	3.14(a)	 	Owned Real Property
		
	3.14(b)	 	Leased Real Property
		
	3.14(c)	 	Subleases of Real Property
		
	3.15(a)	 	Tangible Personal Property
		
	3.15(b)	 	Leases and Subleases of Tangible Personal Property

  

 vi 

Table of Contents

			
	3.16(b)	 	Maintenance of BPH Assets
		
	3.17	 	Customers
		
	3.18	 	Suppliers
		
	5.01(a)	 	Conduct of BPH Business Prior to the Closing
		
	5.01(b)	 	Absence of Certain Changes, Events and Conditions prior to the Closing Date

  

 vii 

Table of Contents

 This ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of April 17, 2007, between
CELSION CORPORATION, a Delaware corporation (the “Seller”) and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Purchaser”). 
 WHEREAS, the Seller is engaged in, among other things, the manufacture (for itself and on behalf of others), marketing, sale, distribution and/or research and development of products using thermal therapy for the
treatment of BPH and prostatitis, including the Products (the “BPH Business”); 
 WHEREAS, the Seller and the Purchaser have
entered into that certain Transaction Agreement, dated as of January 20, 2003 (the “Original Transaction Agreement”), the First Amendment to Transaction Agreement, dated as of August 8, 2005 (the “First
Amendment”) and the Second Amendment to Transaction Agreement, dated as of April 17, 2007 (the “Second Amendment” and together with the Original Transaction Agreement, the First Amendment and all exhibits and schedules
thereto, the “Transaction Agreement”), pursuant to which the Seller granted to the Purchaser the Option, which gives the Purchaser the right to acquire the BPH Business; 
 WHEREAS, pursuant to the First Amendment, the Purchaser has loaned to the Seller an aggregate amount of $15,000,000 (the “Loan”), which
is evidenced by convertible secured promissory notes dated August 8, 2005, February 2, 2006 and July 28, 2006 (collectively, the “Notes”); 
 WHEREAS, the Seller wishes to sell to the Purchaser, and the Purchaser wishes to purchase from the Seller, the BPH Business, including all right, title and interest of the Seller in and to certain property and assets
of the BPH Business, and in connection therewith, the Purchaser is willing to assume certain liabilities of the Seller relating thereto, all upon the terms and subject to the conditions set forth herein; 
 NOW, THEREFORE, in consideration of the premises and the mutual representations, agreements and covenants set forth herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Seller and the Purchaser hereby agree as follows: 
 
ARTICLE I 
 DEFINITIONS 
 
SECTION 1.01 Certain Defined Terms. As used in this Agreement, the following terms shall have the following meanings: 
 “Acquisition Documents” means this Agreement, the Ancillary Agreements, and any certificate, or other document delivered pursuant to this Agreement or the transactions contemplated by this Agreement.

 “Action” means any Claim, action, suit, arbitration, inquiry, proceeding or investigation by or before any Governmental
Authority. 

Table of Contents

 “Affiliate” means, with respect to any specified Person, any other Person that directly,
or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such specified Person. 
 “AMS Proceeding” means the patent infringement claims filed on April 27, 2006 in the United States District Court for the District of Minnesota (Civil Action No. 06-1606 JMR/FLN) and September 28, 2006 in the
United States District Court for the District of Delaware (Civil Action No. 06-606-SLR) by American Medical Systems and AMS Research Corporation against the Seller. 
 “AMS Settlement and License Agreement” means the Settlement and License Agreement among American Medical Systems, AMS Research Corporation and the Seller dated as of February 7, 2007, a copy of
which is attached hereto as Exhibit 1.01(a). 
 “Ancillary Agreements” means the Bill of Sale, the Assignments of
Intellectual Property, the Transition Services Agreement and the Assumption Agreement. 
 “Assignments of Intellectual
Property” means the assignments of Intellectual Property to be executed by the Seller on the Closing Date, substantially in the form of Exhibit 1.01(b). 
 “Assumption Agreement” means the Assumption Agreement to be executed by the Purchaser and the Seller on the Closing Date, substantially in the form of Exhibit 1.01(c). 
 “Bill of Sale” means the Bill of Sale and Assignment to be executed by the Seller on the Closing Date, substantially in the form of
Exhibit 1.01(d). 
 “BPH” means benign prostatic hyperplasia. 
 “BPH 800” means the Microwave BPH 800 System, consisting of the Control Unit and the Catheter Kit. 
 “BPH Intellectual Property” means all Intellectual Property used in or related to the BPH Business. 
 “Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by Law to be closed
in Columbia, Maryland or Boston, Massachusetts. 
 “Catheter Kit” means the single-use disposable components of the Product.

 “Claims” means any and all administrative, regulatory or judicial actions and all suits, petitions, appeals, demands,
demand letters, claims, liens, notices of noncompliance or violation, investigations, proceedings, consent orders or consent agreements. 
 “Code” means the Internal Revenue Code of 1986, as amended through the date hereof. 
  

 2 

Table of Contents

 “control” (including the terms “controlled by” and “under
common control with”), with respect to the relationship between or among two or more Persons, means the possession, directly or indirectly or as trustee, personal representative or executor, of the power to direct or cause the direction of
the affairs or management of a Person, whether through the ownership of voting securities, as trustee, personal representative or executor, by contract, credit arrangement or otherwise. 
 “Control Unit” means the reusable capital equipment component of the Product. 
 “Copyrights” means copyrights in works of authorship of any type, including mask works, computer software, programs and databases,
registrations and applications for registrations thereof throughout the world, all rights therein provided by international treaties and conventions, all moral and common law rights thereto, and all other rights associated therewith. 
 “Distribution Agreement” means that certain Distribution Agreement between the Seller and the Purchaser referred to in the Transaction
Agreement. 
 “Encumbrance” means any security interest, pledge, hypothecation, mortgage, lien (including, without
limitation, environmental and tax liens), violation, charge, lease, license, encumbrance, servient easement, adverse claim, reversion, reverter, preferential arrangement, restrictive covenant, condition or restriction of any kind, including, without
limitation, any restriction on the use, voting, transfer, receipt of income or other exercise of any attributes of ownership. 
 “Environment” means surface waters, groundwaters, soil, subsurface strata and ambient air. 
 “Environmental Claims” means any Claims relating in any way to any Environmental Law or any Environmental Permit, including, without limitation, (a) any and all Claims by Governmental Authorities for enforcement,
cleanup, removal, response, remedial or other actions or damages pursuant to any applicable Environmental Law and (b) any and all Claims by any Person seeking damages, contribution, indemnification, cost recovery, compensation or injunctive
relief resulting from Hazardous Materials or arising from alleged injury or threat of injury to health, safety or the Environment. 
 “Environmental Laws” means all Laws, now in effect and as amended, and any judicial or administrative interpretation thereof, including any judicial or administrative order, consent decree or judgment, relating to the
environment, health, safety, natural resources or Hazardous Materials, including, without limitation, the Comprehensive Environmental Response, Compensation and Liability Act of 1980; the Resource Conservation and Recovery Act, 42 U.S.C.
§§ 6901 et seq.; the Hazardous Materials Transportation Act, 49 U.S.C. §§ 6901 et seq.; the Clean Water Act, 33 U.S.C. §§ 1251 et seq.; the Toxic Substances Control Act, 15
U.S.C. §§ 2601 et seq.; the Clean Air Act, 42 U.S.C. §§ 7401 et seq.; the Safe Drinking Water Act, 42 U.S.C. §§ 300f et seq.; the Atomic Energy Act, 42 U.S.C. §§ 2011
et seq.; the Federal Insecticide, Fungicide and Rodenticide Act, 7 U.S.C. §§ 136 et seq.; and the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301 et seq. 
  

 3 

Table of Contents

 “Environmental Permits” means all permits, approvals, identification numbers, licenses
and other authorizations required under or issued pursuant to any applicable Environmental Law. 
 “FDA” means the United
States Food and Drug Administration, or any successor entity. 
 “First Payment” means $30,000,000, less the sum of the
aggregate outstanding principal and accrued interest payable under the Notes as of the Closing Date. 
 “GAAP” means United
States generally accepted accounting principles and practices in effect from time to time applied consistently throughout the periods involved. 
 “Governmental Authority” means any United States or non-United States federal, national, supranational, state, provincial, local, or similar government, governmental, regulatory or administrative authority, agency,
department, bureau, council or commission or any court, tribunal, or judicial or arbitral body. 
 “Governmental Order”
means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority. 
 “Hazardous Materials” means (a) petroleum and petroleum products, radioactive materials, asbestos-containing materials, urea formaldehyde foam insulation, transformers or other equipment that contain polychlorinated
biphenyls and radon gas, (b) any other chemicals, materials or substances defined as or included in the definition of “hazardous substances”, “hazardous wastes”, “hazardous materials”, “extremely hazardous
wastes”, “restricted hazardous wastes”, “toxic substances”, “toxic pollutants”, “contaminants” or “pollutants”, or words of similar import, under any applicable Environmental Law, and
(c) any other chemical, material or substance which is regulated by any Environmental Law. 
 “HSR Act” means the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder. 
 “Improvements” means any additions, developments, enhancements, updates and other changes in the Products or any components thereof, including any extensions of the label claims for any Products and any new designs for any
Product. 
 “Indebtedness” means, with respect to any Person, (a) all indebtedness of such Person, whether or not
contingent, for borrowed money, (b) all obligations of such Person for the deferred purchase price of property or services, (c) all obligations of such Person evidenced by notes, bonds, debentures or other similar instruments, (d) all
indebtedness created or arising under any conditional sale or other title retention agreement with respect to property acquired by such Person (even though the rights and remedies of the seller or lender under such agreement in the event of default
are limited to repossession or sale of such property), (e) all obligations of such Person as lessee under leases that have been or should be, in accordance with GAAP, recorded as capital leases, (f) all obligations, contingent or
otherwise, of such Person under acceptance, letter of credit or similar facilities, (g) all Indebtedness of others referred to in clauses (a) through (f) above guaranteed directly or indirectly in any manner by such Person and
(h) all Indebtedness 

  

 4 

Table of Contents

 
referred to in clauses (a) through (f) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or
otherwise, to be secured by) any Encumbrance on property (including, without limitation, accounts and contract rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such Indebtedness. 

“Indemnified Party” means a Purchaser Indemnified Party or a Seller Indemnified Party, as the case may be. 
 “Indemnifying Party” means the Seller pursuant to Section 7.02 and the Purchaser pursuant to Section 7.03, as the case may be.

 “Intellectual Property” means (a) Patents, (b) Trademarks, (c) Copyrights, (d) Trade Secrets and
(e) Software. 
 “Inventories” means all raw materials, work-in-process, finished goods, goods in transit, packaging,
labels and supplies related to the BPH Business and maintained, held or stored by or for the Seller on the Closing Date, and any prepaid deposits for any of the same. 
 “IRS” means the Internal Revenue Service of the United States. 
 “Knowledge” means the knowledge of the directors and officers of the Seller, after due inquiry. 
 “Law” means any United States or non-United States federal, national, supranational, state, provincial, local or similar statute, law, ordinance, regulation, rule, code, order, requirement or rule of law (including, without
limitation, common law). 
 “Leased Real Property” means the real property leased by the Seller that is primarily used in
the BPH Business, as tenant, together with all buildings and other structures, facilities or improvements currently or hereafter located thereon, all fixtures, systems, equipment and items of personal property of the Seller primarily used in the BPH
Business attached or appurtenant thereto and all easements, licenses, rights and appurtenances relating to the foregoing. 
 “Liabilities” means any and all debts, liabilities and obligations, whether accrued or fixed, absolute or contingent, matured or unmatured or determined or determinable, including, without limitation, those arising under
any Law (including, without limitation, any Environmental Law), Action or Governmental Order and those arising under any contract, agreement, arrangement, commitment or undertaking. 
 “Licensed Intellectual Property” means all BPH Intellectual Property licensed to the Seller pursuant to the Seller IP Agreements.

 “Material Adverse Effect” means any circumstance, change or effect that, individually or in the aggregate with all other
circumstances, changes or effects: (a) is materially adverse to the business, assets, results of operations, financial condition or prospects of the BPH Business or (b) is materially adverse to the ability of the Seller to consummate the
transactions contemplated by this Agreement, except (i) any change resulting from the announcement or pendency of any transactions contemplated by this Agreement or (ii) any change resulting from 

  

 5 

Table of Contents

 
conditions generally affecting the industry in which the Seller operates provided such conditions do not disproportionately affect the Seller or from changes
in general economic conditions. 
 “Net Present Value” means the present value of any Purchaser Amounts calculated using an
annual discount rate of 10%. In the event that any Purchaser Amounts are to be based upon future product sales or other similar measures, the Net Present Value of such future Purchaser Amounts shall be calculated using the most recent projections of
the Purchaser for the applicable product and the applicable periods that were not prepared for the purposes of making such calculations. In the event that the Purchaser has not prepared projections required by the preceding sentence, the Purchaser
shall prepare the applicable projections based upon its own good faith estimates. 
 “Option Exercise Price” has the meaning
given such term in the Transaction Agreement. 
 “Owned Intellectual Property” means all BPH Intellectual Property owned by
the Seller. 
 “Owned Real Property” means the real property owned by the Seller that is primarily used in the BPH Business,
together with all buildings and other structures, facilities or improvements currently or hereafter located thereon, all fixtures, systems, equipment and items of personal property of the Seller that are primarily used in the BPH Business attached
or appurtenant thereto and all easements, licenses, rights and appurtenances relating to the foregoing. 
 “Patents” means
United States and non-United States patents, patent applications and statutory invention registrations, including reissues, divisions, continuations, continuations-in-part, extensions and reexaminations thereof, and all rights therein provided by
international treaties and conventions. 
 “Permitted Encumbrances” means such of the following as to which no enforcement,
collection, execution, levy or foreclosure proceeding shall have been commenced and as to which the Seller is not otherwise subject to civil or criminal liability due to its existence: (a) liens for Taxes, assessments and governmental charges
or levies not yet due and payable, (b) Encumbrances imposed by Law, such as materialmen’s, mechanics’, carriers’, workmen’s and repairmen’s liens and other similar liens arising in the ordinary course of business
securing obligations that (i) are not overdue for a period of more than 30 days and (ii) are not in excess of $5,000 in the case of a single property or $25,000 in the aggregate at any time, (c) pledges or deposits to secure
obligations under workers’ compensation laws or similar legislation or to secure public or statutory obligations, and (d) minor survey exceptions, reciprocal easement agreements and other customary encumbrances on title to real property
that (i) were not incurred in connection with any Indebtedness, (ii) do not render title to the property encumbered thereby unmarketable and (iii) do not, individually or in the aggregate, materially adversely affect the value of or
the use of such property for its current and anticipated purposes. 
 “Person” means any individual, partnership, firm,
corporation, limited liability company, association, trust, unincorporated organization or other entity, as well as any syndicate 

  

 6 

Table of Contents

 
or group that would be deemed to be a person under Section 13(d)(3) of the Securities Exchange Act of 1934, as amended. 
 “Product” means BPH 800, any of its component products (including, without limitation, the Control Unit and the Catheter Kit) and all
Improvements or substitutes for any of the foregoing. 
 “Product Approvals” means, for any country or other jurisdiction,
those regulatory approvals and licenses required for manufacture, importation, exportation, promotion, pricing, marketing and/or sale of the Products in such country or other jurisdiction. 
 “Purchaser Amounts” means any (i) Losses of the Purchaser or any of its Affiliates resulting from any and all Actions or written
Claims relating to whether any BPH Intellectual Property, Licensed Intellectual Property, Seller IP Agreements or Product conflicts with, infringes, misappropriates, dilutes or otherwise violates the Intellectual Property or other proprietary
rights, including rights of privacy, publicity and endorsement, of any third party (collectively, “Third Party Infringement Claims”), and (ii) payments or royalties that the Purchaser or any of its Affiliates are required to
make as a result of the settlement (whether voluntary or otherwise), judicial determination or other resolution of any Third Party Infringement Claims, including the Net Present Value of any such payments to be made after the date of the first
anniversary of the Closing or the second anniversary of the Closing, as applicable, which, in the case of either subsection (i) or (ii), arise out of or relate to any event or condition occurring or existing on or prior to the Closing Date,
provided, however, that Purchaser Amounts shall not include or apply to any Third Party Infringement Claims to the extent related solely to Improvements to Products made by Purchaser after the Closing Date, and provided
further, however, that in no event shall Purchaser Amounts in the aggregate exceed $15,000,000. 
 “Purchase Disclosure
Schedule” means the Purchase Disclosure Schedule attached hereto delivered by the Seller to the Purchaser pursuant to Section 7.02 of the Transaction Agreement. 
 “Real Property” means the Leased Real Property and the Owned Real Property. 
 “Receivables” means any and all accounts receivable, notes and other amounts receivable from third parties, including, without
limitation, customers and employees, arising from the conduct of the BPH Business, whether or not in the ordinary course, together with any unpaid financing charges accrued thereon. 
 “Regulations” means the Treasury Regulations (including Temporary Regulations) promulgated by the United States Department of Treasury
with respect to the Code or other federal tax statutes. 
 “Release” means disposing, discharging, injecting, spilling,
leaking, leaching, dumping, emitting, escaping, emptying, seeping, placing and the like into or upon any land or water or air or otherwise entering into the Environment. 
 “Remedial Action” means all action to (a) clean up, remove, treat or handle in any other way Hazardous Materials in the Environment, (b) prevent the Release of Hazardous 

  

 7 

Table of Contents

 
Materials so that they do not migrate, endanger or threaten to endanger public health or the Environment, or (c) perform remedial investigations,
feasibility studies, corrective actions, closures and post-remedial or post-closure studies, investigations, operations, maintenance and monitoring. 
 “Second Payment” means $15,000,000, subject to reduction/offset in accordance with Section 7.07. 
 “Seller IP Agreements” means (a) licenses by the Seller to third parties of BPH Intellectual Property, (b) licenses by third parties to the Seller of BPH Intellectual Property, including the
AMS Settlement and License Agreement, (c) agreements between the Seller and third parties relating to the development or use of Intellectual Property used in or related to the BPH Business, including the BPH Intellectual Property, and
(d) consents, settlements, decrees, orders, injunctions, judgments or rulings governing the use, validity or enforceability of BPH Intellectual Property. 
 “Software” means computer software, programs and databases in any form, including Internet web sites, web content and links, source code, object code, operating systems and specifications, data,
databases, database management code, utilities, graphical user interfaces, menus, images, icons, forms, methods of processing, software engines, platforms, and data formats, all versions, updates, corrections, enhancements and modifications thereof,
and all related documentation, developer notes, comments and annotations. 
 “Tax” or “Taxes” means any and
all taxes, fees, levies, duties, tariffs, imposts, and other charges of any kind (together with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any government or taxing authority,
including, without limitation, taxes or other charges on or with respect to income, franchises, windfall or other profits, gross receipts, property, sales, use, capital stock, payroll, employment, social security, workers’ compensation,
unemployment compensation, or net worth; taxes or other charges in the nature of excise, withholding, ad valorem, stamp, transfer, value added, or gains taxes; license, registration and documentation fees; and customs’ duties, tariffs, and
similar charges. 
 “Third Payment” means $15,000,000, subject to reduction in accordance with Section 2.08(a).

 “Trade Secrets” means trade secrets, know-how and other confidential or proprietary technical, business and other
information, including manufacturing and production processes and techniques, research and development information, technology, drawings, specifications, designs, plans, proposals, scientific, clinical and technical data, financial, marketing and
business data, pricing and cost information, business and marketing plans, customer and supplier lists and information, and all rights in any jurisdiction to limit the use or disclosure thereof. 
 “Trademarks” means trademarks, service marks, trade dress, logos, trade names, corporate names, URL addresses, domain names and symbols,
slogans and other indicia of source or origin, including the goodwill of the business symbolized thereby or associated therewith, 

  

 8 

Table of Contents

 
common law rights thereto, registrations and applications for registration thereof throughout the world, all rights therein provided by international
treaties and conventions, and all other rights associated therewith. 
 
SECTION 1.02 Definitions. The following terms have the meanings set forth in the Sections set forth below: 
  

			
	 Definition
	  	Location
	 “Agreement”
	  	Preamble
	 “Assumed Liabilities”
	  	2.02(a)
	 “Board Recommendation”
	  	5.12
	 “BPH Assets”
	  	2.01(a)
	 “BPH Business”
	  	Recitals
	 “BPH Material Contracts”
	  	3.12(a)
	 “Closing”
	  	2.04
	 “Closing Date”
	  	2.04
	 “Conditional Amounts”
	  	2.08(a)(ii)
	 “Excluded Assets”
	  	2.01(b)
	 “Excluded Liabilities”
	  	2.02(b)
	 “Financial Statements”
	  	3.04(a)(i)
	 “Interim Financial Statements”
	  	3.04(a)(ii)
	 “Loss”
	  	7.02
	 “Prime Rate”
	  	2.09
	 “Proxy Statement”
	  	5.12(b)
	 “Purchaser”
	  	Preamble
	 “Purchaser Amounts Note”
	  	2.10
	 “Purchase Price”
	  	2.03(a)
	 “Purchaser Indemnified Party”
	  	7.02
	 “Recommendation”
	  	5.12(a)
	 “Requisite Stockholder Approval”
	  	3.01
	 “Restricted Period”
	  	5.06(a)
	 “Returns”
	  	3.19(a)
	 “Seller”
	  	Preamble
	 “Seller Indemnified Party”
	  	7.03
	 “Seller Stockholder Meeting”
	  	5.12(a)
	 “Tangible Personal Property”
	  	3.15(a)
	 “Third Party Claims”
	  	7.04
	 “Transition Services Agreement”
	  	5.09

 
SECTION 1.03 Interpretation and Rules of Construction. In this Agreement, except to the extent that the context otherwise requires: 
 (a) when a reference is made in this Agreement to an Article, Section, Exhibit or Schedule, such reference is to an Article or Section of,
or a Schedule to, this Agreement unless otherwise indicated; 
  

 9 

Table of Contents

 (b) the table of contents and headings for this Agreement are for reference purposes only
and do not affect in any way the meaning or interpretation of this Agreement; 
 (c) whenever the words “include”,
“includes” or “including” are used in this Agreement, they are deemed to be followed by the words “without limitation”; 
 (d) the words “hereof”, “herein” and “hereunder” and words of similar import, when used in this Agreement, refer to this Agreement as a whole and not to any particular provision of this
Agreement; 
 (e) all terms defined in this Agreement have the defined meanings when used in any certificate or other document
made or delivered pursuant hereto, unless otherwise defined therein; 
 (f) the definitions contained in this Agreement are
applicable to the singular as well as the plural forms of such terms; 
 (g) any Law defined or referred to herein or in any
agreement or instrument that is referred to herein means such Law or statute as from time to time amended, modified or supplemented, including by succession of comparable successor Laws; 
 (h) references to a Person are also to its permitted successors and assigns; 
 (i) the use of “or” is not intended to be exclusive unless expressly indicated otherwise; 
 (j) all references to the Seller are also to its Affiliates; and 
 (k) all references to “$” are references to United States dollars.. 
 
ARTICLE II 
 PURCHASE AND SALE 
 
SECTION 2.01 Purchase and Sale of BPH Assets. (a) Upon the terms and subject to the conditions of this Agreement, at the Closing, the Seller shall sell, assign, transfer, convey and deliver, or cause to be
sold, assigned, transferred, conveyed and delivered, to the Purchaser, and the Purchaser shall purchase from the Seller the following assets, rights, claims, properties, goodwill and business, other than the Excluded Assets (collectively, the
“BPH Assets”): 
 (i) the BPH Business as a going concern; 
 (ii) the goodwill of the Seller relating to the BPH Business; 
 (iii) all the Owned Real Property, if any, and all leasehold rights in respect of the Leased Real Property, if any; 
  

 10 

Table of Contents

 (iv) all furniture, fixtures, equipment, machinery, vehicles and other tangible personal
property primarily used in the conduct of the BPH Business and not otherwise included in clause (iii) above; 
 (v) all
Control Units, wherever located (including at customer sites), owned by the Seller; 
 (vi) all Inventories; 
 (vii) all Receivables arising from the conduct of the BPH Business following the Closing Date; 
 (viii) all prepaid items, including any ad valorem Taxes, leases and rentals, related to the BPH Business; 
 (ix) all books of account, general, financial, Tax and personnel records, invoices, shipping records, supplier lists, correspondence and
other documents, records and files and any rights thereto owned, associated with or employed by the Seller in connection with the BPH Business, including all correspondence records related to the Product Approvals; 
 (x) all the Seller’s right, title and interest in, to and under the BPH Intellectual Property and the Seller IP Agreements, copies
and tangible embodiments thereof in whatever form or medium, and all rights to sue and recover damages, costs and attorney’s fees for past, present and future infringement, dilution, misappropriation, violation, unlawful imitation or breach
thereof; 
 (xi) all claims, causes of action, choses in action, rights of recovery and rights of setoff of any kind
(including rights to insurance proceeds and rights under and pursuant to all warranties, representations and guarantees made by suppliers of products, materials, or equipment, or components thereof) related to the BPH Business pertaining to or
inuring to the benefit of the Seller; provided, that, all damages, awards, payments and reimbursements of costs inuring to the benefit of the Seller (including all structured settlement or deferred payment awards and rights to insurance
proceeds) arising out of any Action commenced prior to the Closing shall be owned by the Seller, subject to (A) any rights, pursuant to the Distribution Agreement, of BSC or any other BSC Indemnified Party (as such term is defined in the
Distribution Agreement) and (B) any rights, pursuant to the Transaction Agreement, of BSC or any other BSC Indemnified Party (as such term is defined in the Transaction Agreement), in each case, in such Action; 
 (xii) all manufacturing information, sales and promotional literature, lists of former and present suppliers and customers and other
sales-related materials related to the BPH Business, including the Products, owned, used, associated with or employed by the Seller at the Closing Date; 
 (xiii) all scientific, clinical, technical and other data related to the Products; 
  

 11 

Table of Contents

 (xiv) all rights of the Seller under all contracts, licenses, sublicenses, agreements,
leases, commitments, and sales and purchase orders, and under all bids and offers (to the extent such offers are transferable), in each case, related to the BPH Business; 
 (xv) all permits, licenses, agreements, waivers, authorizations and approvals, including all Product Approvals, owned, held or used by the
Seller in connection with, or required for, the BPH Business, to the extent transferable; and 
 (xvi) all the Seller’s
right, title and interest on the Closing Date in, to and under all other assets, rights, claims, properties, goodwill and business of every kind and description and wherever located, whether tangible or intangible, real, personal or mixed, directly
or indirectly owned by the Seller related to the BPH Business. 
 (b) Notwithstanding anything in Section 2.01(a) to the contrary, the
BPH Assets shall exclude the following assets and properties owned by the Seller (the “Excluded Assets”): 
 (i) all Receivables arising from the conduct of the BPH Business on or prior to the Closing Date; 
 (ii) all
insurance policies related to claims by the Seller for Losses arising on or prior to the Closing Date; 
 (iii) all refunds
related to Taxes now or hereafter paid by the Seller or any Affiliate of the Seller, or attributable to the BPH Assets or the BPH Business, relating to any period, or any portion of any period, ending on or prior to the Closing Date; 
 (iv) all minute and stock books of the Seller and any other documents relating to the organization, maintenance and existence of the
Seller as a corporation; 
 (v) all damages, awards, payments and reimbursements of costs inuring to the benefit of the Seller
(including all structured settlement or deferred payment awards and rights to insurance proceeds) arising out of any Action commenced prior to the Closing, other than (A) any rights, pursuant to the Distribution Agreement, of BSC or any other
BSC Indemnified Party (as such term is defined in the Distribution Agreement) and (B) any rights, pursuant to the Transaction Agreement, of BSC or any other BSC Indemnified Party (as such term is defined in the Transaction Agreement), in each
case, in such Action; and 
 (vi) all rights of the Seller under this Agreement and the Ancillary Agreements. 
 
SECTION 2.02 Assumption and Exclusion of Liabilities. (a) Upon the terms and subject to the conditions of this Agreement, at the Closing, the Purchaser shall assume and shall agree to pay, perform and
discharge the following Liabilities of the Seller, except for the Excluded Liabilities (the “Assumed Liabilities”): 
 (i) all Liabilities with respect to, arising out of or relating to the ownership, possession or use of the BPH Assets or the operation of the BPH Business, in each case, by the Purchaser after the Closing Date, including all Claims or
Losses related in whole or in 

  

 12 

Table of Contents

 
part to injuries and losses from products or services manufactured, produced, filled, packaged, marketed, sold or otherwise distributed by or on behalf of
the Purchaser after the Closing Date; 
 (ii) all Liabilities under all contracts, licenses (including Seller IP Agreements),
sublicenses, agreements, leases, commitments, and sales and purchase orders, and under all bids and offers, in each case, related to the BPH Business, transferred to the Purchaser and to the extent attributable to the period after the Closing Date
(other than Liabilities or obligations attributable to any failure by the Seller to comply with the terms thereof); 
 (iii)
all Claims or Losses arising out of or resulting from the breach of any representation or warranty, covenant or agreement by BSC contained in the Distribution Agreement or resulting from the performance by BSC of its obligations under Sections 2.02
and 2.05 of the Distribution Agreement; and 
 (iv) all Liabilities arising after the Closing Date relating to the employment
by the Purchaser of any employees of the Seller arising in the course of such employment. 
 (b) Notwithstanding subsection (a) above,
the Seller shall retain, and shall be responsible for paying, performing and discharging when due, and the Purchaser shall not assume or have any responsibility for, all Liabilities of the Seller as of the Closing Date other than the Assumed
Liabilities (the “Excluded Liabilities”), including, without limitation: 
 (i) all Indebtedness of the
Seller; 
 (ii) all Liabilities relating to employees of the Seller, including all Liabilities under any of the Seller’s
employee benefits agreements, plans or other arrangements; 
 (iii) all accounts payable and other accrued liabilities with
respect to the BPH Business incurred on or prior to the Closing Date; 
 (iv) all Taxes now or hereafter owed by the Seller or
any Affiliate of the Seller, or attributable to the BPH Assets or the BPH Business, relating to any period, or any portion of any period, ending on or prior to the Closing Date; 
 (v) all Liabilities pursuant to Environmental Law arising from or related to any action, event, circumstance or condition related to the
BPH Business or the Real Property, in each case occurring or existing on or prior to the Closing Date; 
 (vi) all Claims or
Losses related in whole or in part to injuries and losses from products or services manufactured, produced, filled, packaged, marketed, sold or otherwise distributed by or on behalf of the Seller on or prior to the Closing Date; 
 (vii) all Liabilities arising out of any action, suit, proceeding or investigation pending or threatened as of, or arising out of or
relating to any event or condition occurring or existing on or prior to, the Closing Date; 
  

 13 

Table of Contents

 (viii) all Liabilities under all contracts, licenses, sublicenses, agreements, leases,
subleases, commitments, and sales and purchase orders, and under all bids and offers, in each case related to the BPH Business to the extent arising on or prior to the Closing Date or otherwise attributable to any failure by the Seller to comply
with the terms thereof; 
 (ix) all Liabilities relating to or arising out of the Excluded Assets; and 
 (x) all other Liabilities with respect to, arising out of or relating to the ownership, possession or use of the BPH Assets or the
operation of the BPH Business by the Seller or any Affiliate of the Seller prior to the Closing Date. 
 
SECTION 2.03 Purchase Price; Allocation of Purchase Price. (a) The aggregate purchase price for the BPH Assets shall be the sum of the First Payment, the Second Payment and the Third Payment (the
“Purchase Price”), payable in accordance with Sections 2.06, 2.07 and 2.08. 
 (b) The Purchaser shall
prepare and deliver to the Seller (at least three Business Days prior to the Closing Date) a schedule allocating, as of the Closing Date, the sum of the Purchase Price and the Assumed Liabilities, among the BPH Assets, the Purchaser’s rights
under this Agreement and the Ancillary Agreements, in conformity with Section 1060 of the Code and the regulations thereunder. The Purchaser and the Seller shall thereafter, in good faith, mutually agree to such allocation on or prior to the
Closing Date. The Purchaser and the Seller in connection with their respective U.S. federal, state and local Tax returns and other filings (including Internal Revenue Service Form 8594) shall not take any position inconsistent with such treatment
and allocation. 
 
SECTION 2.04 Closing. Subject to the terms and conditions of this Agreement, the sale and purchase of the BPH Assets and the assumption of the Assumed Liabilities contemplated by this Agreement shall take place at
a closing (the “Closing”) to be held at the offices of Shearman & Sterling, 599 Lexington Avenue, New York, New York at 10:00 A.M. New York time on the fifth Business Day following the satisfaction or waiver of all
conditions to the obligations of the parties set forth in Sections 6.01, 6.02 and 6.03 (other than those which by their nature are to be satisfied at the Closing) or at such other place or at such other time or on such other date as the Seller and
the Purchaser may mutually agree upon in writing (the day on which the Closing takes place being the “Closing Date”). 
 
SECTION 2.05 Closing Deliveries by the Seller. At the Closing, the Seller shall deliver or cause to be delivered to the Purchaser: 
 (a) the Bill of Sale, the Assignment of Intellectual Property and such other instruments, in form and substance satisfactory to the
Purchaser, as may be requested by the Purchaser to transfer the BPH Assets to the Purchaser or evidence such transfer on the public records; 
 (b) executed counterparts of the Assumption Agreement and the Transition Services Agreement; 
 (c) a receipt for the First Payment and the Notes; and 
  

 14 

Table of Contents

 (d) the certificate and other documents required to be delivered pursuant to
Section 6.02. 
 
SECTION 2.06 Closing Deliveries by the Purchaser. At the Closing, the Purchaser shall deliver to the Seller: 
 (a) the First Payment less the amount of principal and accrued interest outstanding under the Notes by wire transfer in immediately available funds to an account designated by the Purchaser at least two Business Days prior to the Closing
Date; 
 (b) the Notes for cancellation; 
 (c) executed counterparts of the Assumption Agreement and the Transition Services Agreement; and 
 (d) the
certificate required to be delivered pursuant to Section 6.01. 
 
SECTION 2.07 Second Payment. On the first anniversary of the Closing Date: 
 (a) the Purchaser shall
deliver to the Seller the Second Payment by wire transfer in immediately available funds to an account designated by the Purchaser at least two Business Days prior to the first anniversary of the Closing Date; 
 (b) the Seller shall deliver to the Purchaser a receipt for the Second Payment; and 
 (c) for the avoidance of doubt, Purchaser shall have no right to withhold the Second Payment or otherwise offset against the Second Payment with respect
to any Purchaser Amounts or Conditional Amounts. 
 
SECTION 2.08 Third Payment. On the second anniversary of the Closing Date: 
 (a) the Purchaser shall
deliver to the Seller the Third Payment less the amount of the sum of (i) the Purchaser Amounts and (ii) any amounts that are the subject of Third Party Infringement Claims of the type described in the definition of Purchaser Amounts but
which have not become Losses of the Purchaser (“Conditional Amounts”) prior to the date of the second anniversary of the Closing Date, by wire transfer in immediately available funds to an account designated by the Purchaser at
least two Business Days prior to the second anniversary of the Closing Date; provided that the aggregate amounts deducted from the Third Payment under this Section 2.08(a) shall not exceed $10,000,000; and 
 (b) the Seller shall deliver to the Purchaser a receipt for the Third Payment. 
 
SECTION 2.09 Release of Excess Deductions. Following the final resolution of any matter in respect of which the Purchaser deducted a Conditional Amount from the Third Payment pursuant to Section 2.08(a)(ii),
any portion of such Conditional Amount that is in excess of the Purchaser Amounts actually incurred by the Purchaser in connection with the resolution of 

  

 15 

Table of Contents

 
such matter shall be paid, together with interest accrued thereon from the second anniversary of the Closing Date at a rate per annum equal to 1% above that
rate of interest that The Bank of America publicly announces as, and declares to be, the regular commercial prime rate of interest of such bank that such bank uses as a guideline for, and a standard in determining, actual interest rates charged
commercial borrowers (the “Prime Rate”), by the Purchaser to the Seller as soon as reasonably practicable after such final resolution by wire transfer in immediately available funds to an account designated by the Seller. Changes in
the interest rates applicable in determining the interest due hereunder shall be made daily as of and immediately upon the occurrence of changes in the Prime Rate. 
 SECTION 2.10 Purchaser Amounts Note. From and after the second anniversary of the Closing Date and subject to the limitation set forth in Section 7.05, upon receipt of a written request from the Purchaser
including reasonable supporting detail evidencing Purchaser’s calculation of the Purchaser Amounts or Conditional Amounts, the Seller shall deliver one or more duly executed original promissory notes having an aggregate principal amount of not
more than $5 million, in the form of Exhibit 2.10 hereto (the “Purchaser Amounts Note”), evidencing the Seller’s obligation to pay, upon the terms and subject to the conditions set forth in the Purchaser Amounts Note, an amount
equal to any Purchaser Amounts in respect of which the Purchaser is entitled to be indemnified under Section 7.02(e) and for which the Purchaser has not previously received payment as a result of a deduction from the Third Payment pursuant to
Section 2.08(a), Section 7.02(e) or otherwise. If the Purchaser Amounts actually paid by Purchaser to third parties are less than the Conditional Amounts estimated by Purchaser in establishing the initial principal amount of a Purchaser
Amounts Note, the principal amount of such Purchaser Amounts Note shall be reduced on a dollar-for-dollar basis to reflect such reduced Purchaser Amounts effective as of the date such final Purchaser Amounts are calculable. If the Purchaser has
effected a Conversion (as defined in the Purchaser Amounts Note) or the Purchaser Amount Note has been repaid by the Seller prior to any such reduction in principal, the Purchaser shall pay to the Seller the amount of such reduction, together with
interest accrued thereon calculated in the manner set forth in Section 2.09, as soon as reasonably practicable after the date such final Purchaser Amounts are calculable by wire transfer in immediately available funds to an account designated
by the Seller. 
 
ARTICLE III 
 REPRESENTATIONS AND WARRANTIES 
 OF THE SELLER 
 As an inducement to the Purchaser to enter into this Agreement,
the Seller hereby represents and warrants to the Purchaser as follows: 
 
SECTION 3.01 Organization, Authority and Qualification of the Seller. (a) The Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all
necessary power and authority to enter into this Agreement and the Ancillary Agreements, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The Seller is duly licensed or
qualified to do business and is in good standing in each jurisdiction in which the properties owned or leased by it or the operation of its business makes such licensing or qualification necessary, except to the extent that the failure to be so
licensed or qualified and in good standing would not (a) adversely 

  

 16 

Table of Contents

 
affect the ability of the Seller to carry out its obligations under, and to consummate the transactions contemplated by, this Agreement and the Ancillary
Agreements, (b) adversely affect the ability of the Seller to conduct the BPH Business or (c) otherwise have a Material Adverse Effect. The entering into of this Agreement by the Seller and the execution and delivery of the Ancillary
Agreements by the Seller, the performance by the Seller of its obligations hereunder and thereunder and, subject to the approval of the transactions contemplated by this Agreement by the affirmative vote of the holders of a majority of the
outstanding shares of common stock, par value $0.01 per share, of the Seller (the “Requisite Stockholder Approval”), the consummation by the Seller of the transactions contemplated hereby and thereby have been duly authorized by all
requisite action on the part of the Seller and its stockholders. This Agreement has been duly entered into by the Seller, and upon their execution, the Ancillary Agreements shall have been duly executed and delivered by the Seller, and this
Agreement constitutes, and (assuming due authorization, execution and delivery by the Purchaser) upon their execution the Ancillary Agreements shall constitute, legal, valid and binding obligations of the Seller, enforceable against the Seller in
accordance with their respective terms, subject to (i) applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and other laws relating to or affecting the rights of creditors generally (including, without
limitation, fraudulent conveyance laws) and (ii) the exercise of judicial discretion in accordance with general principles of equity, regardless of whether such enforceability is considered in a proceeding at law or in equity, including,
without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance, or injunctive relief. 
 (b) The Board of Directors of the Seller, by resolutions duly adopted by unanimous written consent or unanimous vote of those voting at a meeting duly called and held (and not subsequently rescinded or modified in any
way), has duly (i) determined that it is advisable and in the best interests of the Seller to enter into this Agreement, (ii) approved the execution, delivery and performance of this Agreement and the consummation of the transactions
contemplated hereby and (iii) resolved to recommend that the stockholders of the Seller approve the transactions contemplated by this Agreement, and directed that this Agreement be submitted for consideration by such stockholders, at the Seller
Stockholder Meeting. 
 
SECTION 3.02 No Conflict. Except as set forth in Section 3.02 of the Purchase Disclosure Schedule, assuming compliance with the notification requirements of the HSR Act and satisfaction of the condition set
forth in Section 6.01(c), the entering into and performance of this Agreement and the execution, delivery and performance of the Ancillary Agreements by the Seller do not and will not (a) violate, conflict with or result in the breach of
any provision of the Certificate of Incorporation or By-laws of the Seller, (b) conflict with or violate any Law or Governmental Order applicable to the Seller or any of its assets, properties or businesses including, without limitation, the
BPH Business, or (c) conflict with, result in any breach of, constitute a default (or event which with the giving of notice or lapse of time, or both, would become a default) under, require any consent under, or give to others any rights of
termination, amendment, acceleration, suspension, revocation or cancellation of, or result in the creation of any Encumbrance on any of the BPH Assets pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease, sublease, license,
permit, franchise or other instrument or arrangement to which the Seller is a party or by which any of the such assets or properties is bound or affected. 
  

 17 

Table of Contents

 
SECTION 3.03 Governmental Consents and Approvals. Except as set forth in Section 3.03 of the Purchase Disclosure Schedule, the performance of this Agreement and the execution, delivery and performance of
each Ancillary Agreement by the Seller do not and will not require any consent, approval, authorization or other order of, action by, filing with or notification to, any Governmental Authority, except in connection with attaining the Requisite
Stockholder Approval and the notification requirements of the HSR Act. 
 
SECTION 3.04 Financial Information; Books and Records. (a) True and complete copies of (i) the unaudited statement of net assets of the BPH Business for the two fiscal years ended immediately prior to
the date hereof and the related unaudited statements of income and cash flows, together with all related notes and schedules thereto (all such financial statements being the “Financial Statements”) and (ii) the unaudited
statement of net assets of the BPH Business as of the quarter ended immediately prior to the date hereof and the related unaudited statements of income and cash flows (all such financial statements being the “Interim Financial
Statements”) have been delivered by the Seller to the Purchaser. The Financial Statements and the Interim Financial Statements (A) were prepared in accordance with the books of account and other financial records of the Seller,
(B) present fairly the financial condition and results of operations of the BPH Business as of the dates thereof or for the periods covered thereby, (C) have been prepared in accordance with GAAP applied on a basis consistent with the past
practices of the Seller in the preparation of its audited financial statements and (D) include all adjustments (consisting only of normal recurring accruals) that are necessary for a fair presentation of the financial condition and the results
of operations of the BPH Business as of the dates thereof or for the periods covered thereby, subject in the case of the Interim Financial Statements to normal recurring year-end adjustments and the absence of footnotes. 
 (b) The books of account and other financial records of the Seller related to the BPH Business: (i) reflect all items of income and expense and all
assets and Liabilities required to be reflected therein in accordance with GAAP applied on a basis consistent with the past practices of the Seller in the preparation of its audited financial statements, (ii) are in all material respects
complete and accurate, and do not contain or reflect any material inaccuracies or discrepancies and (iii) have been maintained in accordance with good business and accounting practices. 
 
SECTION 3.05 Absence of Undisclosed Liabilities. Except as set forth in Section 3.05 of the Purchase Disclosure Schedule, there are no Liabilities of the BPH Business, other than Liabilities
(a) reflected or reserved against the Interim Financial Statement, or (b) incurred since the date of the Interim Financial Statement in the ordinary course of business, consistent with past practice, of the Seller and which do not and
could not have a Material Adverse Effect. 
 
SECTION 3.06 Inventories. The values at which all Inventories are carried on the Interim Financial Statement reflect the historical inventory valuation policy of the Seller of stating such Inventories at the
lower of cost or market value. Except as set forth in Section 3.06 of the Purchase Disclosure Schedule, (a) the Seller has good and marketable title to the Inventories free and clear of all Encumbrances, (b) the Inventories do not
consist of, in any material amount, items that are obsolete or damaged, (c) the Inventories do not consist of any items held on consignment and (d) the Inventories are in good and merchantable condition in all material respects, are
suitable and usable for the purposes for which they are intended and are in a condition such that they can be sold in the ordinary course of the BPH Business consistent with past practice. 
  

 18 

Table of Contents

 
SECTION 3.07 Absence of Certain Changes, Events and Conditions. (a) Since the date of the Interim Financial Statements through the date hereof, the BPH Business has been conducted in the ordinary course and
consistent with past practice. As amplification and not limitation of the foregoing, except as set forth in Section 3.07 of the Purchase Disclosure Schedule, since such date, the Seller has not: 
 (i) permitted or allowed any of the BPH Assets to be subjected to any Encumbrance, other than Permitted Encumbrances and Encumbrances that
will be released at or prior to the Closing; 
 (ii) written down or written up (or failed to write down or write up in
accordance with GAAP consistent with past practice) the value of any Inventories or Receivables or revalued any of the BPH Assets other than in the ordinary course of business consistent with past practice and in accordance with GAAP; 
 (iii) made any change in any method of accounting or accounting practice or policy used by the Seller, other than such changes required by
GAAP; 
 (iv) amended, terminated, cancelled or compromised any material claims of the Seller (related to the BPH Business) or
waived any other rights of substantial value to the Seller (related to the BPH Business); 
 (v) sold, transferred, leased,
subleased, licensed, sublicensed or otherwise disposed of, any properties or assets, real, personal or mixed, of the BPH Business (including, without limitation, the Owned Intellectual Property, the Licensed Intellectual Property or the Seller IP
Agreements), other than the sale of Inventories in the ordinary course of business consistent with past practice; 
 (vi)
merged with, entered into a consolidation with or acquired an interest of 5% or more in any Person or acquired a substantial portion of the assets or business of any Person or any division or line of business thereof, or otherwise acquired any
material assets, in each case with respect to the BPH Business; 
 (vii) made any capital expenditure or commitment for any
capital expenditure with respect to the BPH Business in excess of $150,000 individually or $500,000 in the aggregate; 
 (viii) issued any sales orders or otherwise agreed to make any purchases involving exchanges in value in excess of $50,000 individually or $150,000 in the aggregate, other than in the ordinary course of business consistent with past
practice; 
 (ix) made any material changes in the customary methods of operations of the BPH Business, including, without
limitation, practices and policies relating to manufacturing, purchasing, Inventories, marketing, selling and pricing; 
 (x)
failed to pay any creditor any material amount owed to such creditor when due; 
  

 19 

Table of Contents

 (xi) permitted to lapse or become abandoned any BPH Intellectual Property (or any
registration or grant thereof or any application relating thereto) to which, or under which, the Seller has any right, title, interest or license; 
 (xii) failed to maintain the Seller’s plant, property and equipment related to the BPH Business in good repair and operating condition, ordinary wear and tear excepted; 
 (xiii) suffered any casualty loss or damage with respect to any of the BPH Assets which in the aggregate have a replacement cost of more
than $50,000, whether or not such loss or damage shall have been covered by insurance; 
 (xiv) amended, modified or consented
to the termination of any BPH Material Contract or the Seller’s rights thereunder; 
 (xv)(i) abandoned, sold, assigned,
or granted any security interest in or to any item of the Owned Intellectual Property, Licensed Intellectual Property or Seller IP Agreements, including, without limitation, failing to perform or cause to be performed all applicable filings,
recordings and other acts, and pay or caused to be paid all required fees, royalties and taxes, to maintain and protect its interest in such Owned Intellectual Property, Licensed Intellectual Property or Seller IP Agreements, (ii) granted to
any third party any license with respect to any Owned Intellectual Property or Licensed Intellectual Property, (iii) developed, created or invented any BPH Intellectual Property jointly with any third party with respect to which the Seller
would not retain full ownership in such BPH Intellectual Property, or (iv) disclosed, or allow to be disclosed, any confidential BPH Intellectual Property, unless such BPH Intellectual Property is subject to a confidentiality or non-disclosure
covenant protecting against disclosure thereof; 
 (xvi) made, revoked or changed any express or deemed election, changed any
method of Tax accounting or settled or compromised any liability with respect to Taxes relating to the BPH Business; or 
 (xvii) agreed, whether in writing or otherwise, to take any of the actions specified in this Section 3.07 or granted any options to purchase, rights of first refusal, rights of first offer or any other similar rights or commitments
with respect to any of the actions specified in this Section 3.07, except as expressly contemplated by this Agreement and the Ancillary Agreements. 
 (b) Since the date of the Financial Statement for the fiscal year immediately preceding the date hereof through the date hereof, the BPH Business has not suffered a Material Adverse Effect. 
 
SECTION 3.08 Litigation. Except as set forth in Section 3.08 of the Purchase Disclosure Schedule (which, with respect to each Action set forth therein, sets forth the parties, nature of the proceeding, date
commenced, status, amount of charges or other relief sought and, if applicable, paid or granted), there are no Actions by or against the Seller or any Affiliate thereof relating to the BPH Business or affecting any of the BPH Assets or the BPH
Business pending before any Governmental Authority (or, to the Knowledge of the Seller, threatened to be brought by or before any Governmental Authority). The Seller is not, with respect to either the BPH 

  

 20 

Table of Contents

 
Business or any of the BPH Assets, subject to any Governmental Order (nor, to the Knowledge of the Seller, are there any such Governmental Orders threatened
to be imposed by any Governmental Authority) which has or has had a Material Adverse Effect or could affect the legality, validity or enforceability of this Agreement, any Ancillary Agreement or the consummation of the transactions contemplated
hereby or thereby. 
 
SECTION 3.09 Compliance with Laws. (a) The Seller has conducted and continues to conduct the BPH Business in compliance, in all material respects, with all Laws and Governmental Orders applicable to the
Seller or any of the BPH Assets or the BPH Business, and the Seller is not in violation of any such Law or Governmental Order. 
 (b)
Section 3.09(b) of the Purchase Disclosure Schedule sets forth a brief description of each Governmental Order applicable to the Seller (related to the BPH Business), the BPH Assets or the BPH Business. 
 
SECTION 3.10 Product Approvals. (a) Schedule 3.10(a) of the Purchase Disclosure Schedule sets forth, as of the date thereof, a list of all Product Approvals. 
 (b) The Seller has not sold or otherwise distributed any Products prior to receiving any required Product Approval. The Seller has obtained, in all
countries or jurisdictions where the Seller is marketing the Products, all applicable licenses, registrations, approvals, consents, clearances and authorizations required by any Governmental Authority regulating the safety, effectiveness and market
clearance of the Products to sell, promote and market the Products. 
 (c) The Seller is the sole and exclusive owner of the Product
Approvals and has not granted any right of reference with respect thereto. 
 (d) All manufacturing operations conducted by the Seller and
its Affiliates (or, to the Knowledge of the Seller, by third parties on behalf of the Seller and its Affiliates) relating to the manufacturing and testing of the Products are being conducted in compliance with good manufacturing practices and
quality system regulations. 
 (e) All of the Products are designed, manufactured, labeled, tested and inspected in accordance with the
specifications and standards contained in the Product Approvals. 
 (f) All clinical trials with respect to the Products have been and are
conducted with reasonable care and in accordance with all applicable Laws and the stated protocols for such clinical trials. 
 (g) Neither
the Seller nor any of its Affiliates has received any notice that any Governmental Authority (including the FDA) has commenced or is threatening to initiate any action to withdraw any Product Approval to limit the ability of the Seller to
manufacture (or to have manufactured for it by a third party) or market any Product or to request or recommend the recall or withdrawal of any Product, or commenced or, to the Knowledge of the Seller, threatened to initiate any action to enjoin
production of such Products at any facility. 
 (h) All of the Seller’s submissions to the FDA and any other Governmental Authority,
whether oral, written or electronically delivered, were true, accurate and complete as of 

  

 21 

Table of Contents

 
the date made, and remain true, accurate and complete as of the date hereof, and do not materially misstate any of the statements or information included
therein, or omit to state a material fact necessary to make the statements therein not misleading. 
 (i) The Seller owns or has the right to
use all material regulatory documents, including all material marketing applications, clinical trial applications and other correspondence and reports made to Governmental Authorities, necessary to market and sell the Products as currently marketed
and sold, and the consummation of the transactions contemplated hereby will not impair any such rights in any material respect. 
 (j)
Schedule 3.10(j) of the Purchase Disclosure Schedule lists, in each case with respect to the BPH Business, (i) all products and technologies in development, (ii) current pre-clinical projects and line extension projects, (iii) each
clinical trial in progress or pending, including site, phase and indication and (iv) the current product pipeline. 
 
SECTION 3.11 Environmental Permits and Related Matters. (a) (i) The BPH Business is in compliance with all applicable Environmental Laws and all Environmental Permits; (ii) there has been no
Release of any Hazardous Material on any of the Real Property or, during the period of the Seller’s ownership, lease, use or occupancy thereof, on any property formerly owned, leased, used or occupied by the Seller and primarily used in the BPH
Business; and (iii) there are no Environmental Claims pending or, to the Knowledge of the Seller, threatened against the Seller relating to the BPH Business or the Real Property. 
 (b) Neither entering into of this Agreement or the Ancillary Agreements nor the consummation of the transactions contemplated hereby or thereby will
require any Remedial Action or notice to or consent of Governmental Authorities or third parties pursuant to any applicable Environmental Law or Environmental Permit. 
 
SECTION 3.12 BPH Material Contracts. (a) Section 3.12(a) of the Purchase Disclosure Schedule lists each of the following contracts and agreements (including, without limitation, oral agreements) of the
Seller or any of its Affiliates relating to the BPH Business (such contracts and agreements, being the “BPH Material Contracts”): 
 (i) any purchase, production, sales, agency, distribution, advertising, consulting or outsourcing contract with annual payments in excess of $25,000; 
 (ii) any contract related to the manufacturing of the Products; 
 (iii) any Seller IP Agreement, including patent, copyright and trademark licenses and co-ownership, cooperation and coexistence
agreements; 
 (iv) any collaboration, research and development contract and any other contract relating to scientific and
clinical relationships; 
 (v) all contracts and agreements with any Governmental Authority; 
  

 22 

Table of Contents

 (vi) any contract limiting the freedom of the Seller to engage in any line of business or
to compete with any other Person or restricting or purporting to restrict the ability of the Seller to engage in any type of business or to operate in any geographic area; 
 (vii) other than the Transaction Agreement, any contract granting to any Person a right of first refusal or option or similar right to
purchase or acquire any asset, right or property that would constitute a BPH Asset; 
 (viii) any contract containing
termination, consent or other provisions triggered by the transactions contemplated by this Agreement; 
 (ix) all contracts,
leases and subleases concerning the use, occupancy, management or operation of any Real Property; 
 (x) all contracts with
independent contractors or consultants (or similar arrangements) to which the Seller is a party (related to the BPH Business) and which are not cancellable without penalty or further payment and without more than 30 days’ notice; 
 (xi) all contracts and agreements related to the BPH Business between the Seller, on one hand, and any Affiliate of the Seller, on the
other hand; 
 (xii) any other contract, agreement, invoice, purchase order and other arrangement, for the purchase of
Inventory, spare parts, other materials or personal property primarily used in the BPH Business, with any supplier or for the furnishing of services to the Seller (related to the BPH Business) under the terms of which the Seller: (A) is likely
to pay or otherwise give consideration of more than $50,000 in the aggregate during the current calendar year, (B) is likely to pay or otherwise give consideration of more than $100,000 in the aggregate over the remaining term of such contract
or (C) cannot be cancelled by the Seller without penalty or further payment and without more than 30 days’ notice; 
 (xiii) any other contract, agreement, invoice, sales order and other arrangement, for the sale of Products or other personal property, or for the furnishing of services by the Seller relating to the BPH Business which: (A) is likely to
involve consideration of more than $50,000 in the aggregate during the current calendar year, (B) is likely to involve consideration of more than $100,000 in the aggregate over the remaining term of the contract or (C) cannot be cancelled
by the Seller without penalty or further payment and without more than 30 days’ notice; 
 (xiv) all other contracts and
agreements, whether or not made in the ordinary course of business, which are material to the BPH Business, or the absence of which would have a Material Adverse Effect. 
 (b) Except as set forth in Section 3.12(b) of the Purchase Disclosure Schedule, each BPH Material Contract: (i) is valid and binding on the parties thereto and is in full force and effect, (ii) is
freely and fully assignable to the Purchaser without penalty or other adverse consequences and (iii) upon consummation of the transactions contemplated by this Agreement and the Ancillary Agreements, except to the extent that any consents
required to be obtained under Section 6.02(d) 

  

 23 

Table of Contents

 
are not obtained, shall continue in full force and effect without penalty or other adverse consequence. Neither the Seller nor any of its Affiliates is in
breach of, or default under, any BPH Material Contract. 
 (c) Except as set forth in Section 3.12(c) of the Purchase Disclosure
Schedule, to the Knowledge of the Seller, no other party to any BPH Material Contract is in breach thereof or default thereunder and the Seller has received no notice of termination, cancellation, breach or default under any BPH Material Contract.

 (d) The Seller has made available to the Purchaser true and complete copies of all BPH Material Contracts. 
 
SECTION 3.13 Intellectual Property. (a) Section 3.13(a) of the Purchase Disclosure Schedule sets forth a true and complete list of (i) all patents and patent applications, registered trademarks and
trademark applications, registered copyrights and copyright applications, and domain names included in the Owned Intellectual Property, (ii) all Seller IP Agreements, other than commercially available off-the-shelf computer software licensed
pursuant to shrink-wrap or click-wrap licenses that is not material to the BPH Business and (iii) other Owned Intellectual Property material to the BPH Business. 
 (b) Except as set forth in Section 3.13(b) of the Purchase Disclosure Schedule, to the Knowledge of the Seller, the operation of the BPH Business as previously conducted or as currently conducted and the use of
the Owned Intellectual Property and Licensed Intellectual Property in connection therewith, do not conflict with, infringe, misappropriate, dilute or otherwise violate the Intellectual Property or other proprietary rights, including rights of
privacy, publicity and endorsement, of any third party, and no Actions or Claims are pending or, to the Knowledge of the Seller, threatened against the Seller alleging any of the foregoing. 
 (c) Except as set forth in Section 3.13(c) of the Purchase Disclosure Schedule, the Seller is the exclusive owner of the entire and unencumbered
right, title and interest in and to the Owned Intellectual Property and has the exclusive, unencumbered right to all benefits under the Seller IP Agreements, and the Seller has a valid right to use the Owned Intellectual Property and Licensed
Intellectual Property in the ordinary course of the BPH Business as presently conducted, subject only to the terms of the Seller IP Agreements in the case of the Licensed Intellectual Property. 
 (d) Except as set forth in Section 3.13(d) of the Purchase Disclosure Schedule, no Owned Intellectual Property, or to the Knowledge of the Seller,
any Licensed Intellectual Property, is subject to any outstanding decree, order, injunction, judgment or ruling restricting the use of such Owned Intellectual Property or Licensed Intellectual Property or that would impair the validity or
enforceability of such Owned Intellectual Property or Licensed Intellectual Property. 
 (e) Except as set forth in Section 3.13(e) of
the Purchase Disclosure Schedule, the Owned Intellectual Property and the Licensed Intellectual Property include all of the Intellectual Property used in or related to the conduct of the BPH Business, and there are no other items of Intellectual
Property that are material to the conduct of the BPH Business. The Owned Intellectual 

  

 24 

Table of Contents

 
Property and, to the Knowledge of the Seller, the Licensed Intellectual Property, are existing, valid and enforceable, and have not been adjudged invalid or
unenforceable in whole or part. 
 (f) Except as set forth in Section 3.13(f) of the Purchase Disclosure Schedule, no Actions or Claims
have been asserted or are pending or, to the Knowledge of the Seller, threatened against the Seller (i) based upon or challenging or seeking to deny or restrict the use by the Seller of any of the Owned Intellectual Property or Licensed
Intellectual Property, (ii) alleging that any services provided by, processes used by, or products manufactured or sold by the Seller (in connection with the BPH Business) infringe or misappropriate any Intellectual Property right of any third
party or (iii) alleging that the Licensed Intellectual Property is being licensed or sublicensed in conflict with the terms of any license or other agreement. 
 (g) Except as set forth in Section 3.13(g) of the Purchase Disclosure Schedule, to the Knowledge of the Seller, no person is engaging in any activity that infringes the Owned Intellectual Property or Licensed
Intellectual Property. The Seller has granted no license or other right to any third party with respect to the Owned Intellectual Property or Licensed Intellectual Property. The consummation of the transactions contemplated by this Agreement and the
Ancillary Agreements will not result in the termination or impairment of any of the Owned Intellectual Property or the Seller IP Agreements. 
 (h) The Seller has taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of the Trade Secrets and other confidential BPH Intellectual Property. Except as set forth in Section 3.13(h) of the
Purchase Disclosure Schedule, to the Knowledge of the Seller, (i) there has been no misappropriation of any material Trade Secrets or other material confidential BPH Intellectual Property by any person; (ii) no employee, independent
contractor or agent of the Seller has misappropriated any Trade Secrets of any other person in the course of performance as an employee, independent contractor or agent of the BPH Business; and (iii) no employee, independent contractor or agent
of the Seller has materially defaulted or breached any term of any employment agreement, nondisclosure agreement, assignment of invention agreement or similar agreement or contract relating in any way to the protection, ownership, development, use
or transfer of the Owned Intellectual Property or the Licensed Intellectual Property. 
 
SECTION 3.14 Real Property. (a) Section 3.14(a) of the Purchase Disclosure Schedule lists: (i) the street address of each parcel of Owned Real Property, (ii) the date on which each parcel of
Owned Real Property was acquired, (iii) the current owner of each parcel of Owned Real Property, (iv) information relating to the recordation of the deed pursuant to which each parcel of Owned Real Property was acquired, and (v) the
current use of each parcel of Owned Real Property. 
 (b) Section 3.14(b) of the Purchase Disclosure Schedule lists: (i) the street
address of each parcel of Leased Real Property, (ii) the identity of the lessor, lessee and current occupant (if different from lessee) of each such parcel of Leased Real Property, (iii) the terms (referencing applicable renewal periods)
and rental payment amounts (including all escalations) pertaining to each such parcel of Leased Real Property, and (iv) the current use of each such parcel of Leased Real Property. 
  

 25 

Table of Contents

 (c) The Seller is in peaceful and undisturbed possession of each parcel of Real Property, and there are
no contractual or legal restrictions that preclude or restrict the ability to use the Real Property for the purposes for which it is currently being used. Except as set forth in Section 3.14(c) of the Purchase Disclosure Schedule, the Seller
has not leased or subleased any parcel or any portion of any parcel of Real Property to any other Person and no other Person has any rights to the use, occupancy or enjoyment thereof pursuant to any lease, sublease, license, occupancy or other
agreement, nor has the Seller assigned its interest under any lease or sublease listed in Section 3.14(b) of the Purchase Disclosure Schedule to any third party. 
 
SECTION 3.15 Tangible Personal Property. (a) Section 3.15(a) of the Purchase Disclosure Schedule lists each item or distinct group of machinery, equipment, tools, supplies, furniture, fixtures,
personalty, vehicles and other tangible personal property (the “Tangible Personal Property”) primarily used in the BPH Business. 
 (b) Section 3.15(b) of the Purchase Disclosure Schedule sets forth a true and complete list of all leases and subleases for Tangible Personal Property and any and all material ancillary documents pertaining thereto (including, but not
limited to, all amendments, consents and evidence of commencement dates and expiration dates). 
 
SECTION 3.16 BPH Assets. (a) The Seller owns, leases or has the legal right to use all the BPH Assets and, with respect to contract rights, is a party to and enjoys the right to the benefits of all
contracts, agreements and other arrangements relating to the conduct of the BPH Business. The Seller has good and marketable title to, or, in the case of leased or subleased BPH Assets, valid and subsisting leasehold interests in, all the BPH
Assets, free and clear of all Encumbrances, except Permitted Encumbrances. 
 (b) The BPH Assets constitute all the properties, assets and
rights forming a part of, used or held, and all such properties, assets and rights as are necessary in the conduct of the BPH Business. Except as set forth in Section 3.16(b) of the Purchase Disclosure Schedule, the Seller has caused the BPH
Assets to be maintained in accordance with good business practice, and all the BPH Assets are in good operating condition and repair and are suitable for the purposes for which they are used and intended. 
 (c) The Seller has the complete and unrestricted power and unqualified right to sell, assign, transfer, convey and deliver the BPH Assets or the right to
use the BPH Assets, as applicable, to the Purchaser without penalty or other adverse consequences. Following the consummation of the transactions contemplated by this Agreement and the execution of the instruments of transfer contemplated by this
Agreement, the Purchaser will own, with good, valid and marketable title, or lease, under valid and subsisting leases, or otherwise acquire the interests of the Seller in the BPH Assets, free and clear of any Encumbrances, other than Permitted
Encumbrances, and without incurring any penalty or other adverse consequence, including, without limitation, any increase in rentals, royalties, or license or other fees imposed as a result of, or arising from, the consummation of the transactions
contemplated by this Agreement. 
 
SECTION 3.17 Customers. Listed in Section 3.17 of the Purchase Disclosure Schedule are the names and addresses of all the Seller’s customers of the BPH Business which ordered Products or any other goods
or services from the Seller in any Excluded Market (as such 

  

 26 

Table of Contents

 
term is defined in the Distribution Agreement) for the twelve-month period ended on the last day of the month immediately preceding the date of the Purchase
Disclosure Schedule and the amount for which each such customer was invoiced during such period. The Seller has not received any notice and does not have any Knowledge that any significant customer of the BPH Business has ceased, or will cease, to
use the Products, goods or services of the Seller, or has substantially reduced, or will substantially reduce, the use of such Products, goods or services at any time. 
 
SECTION 3.18 Suppliers. Listed in Section 3.18 of the Purchase Disclosure Schedule are the names and addresses of all the suppliers of the BPH Business from which the Seller ordered raw materials, supplies,
merchandise and other goods for the BPH Business for the twelve-month period ended on the last day of the month immediately preceding the date of the Purchase Disclosure Schedule and the amount for which each such supplier invoiced the Seller during
such period. The Seller has not received any notice that any such supplier will not sell raw materials, supplies, merchandise and other goods to the Purchaser at any time after the Closing Date on terms and conditions substantially similar to those
used in its current sales to the BPH Business, subject only to general and customary price increases. Except as set forth in Section 3.18 of the Purchase Disclosure Schedule, none of the raw materials, supplies, merchandise or other goods
supplied to the BPH Business are such that they are not generally available in the market from more than one source. 
 
SECTION 3.19 Taxes. (a) (i) All material returns, reports and forms (“Returns”) in respect of Taxes required to be filed with respect to the BPH Business have been timely filed, taking
into account all applicable extensions; (ii) all Taxes shown as due on such Returns or otherwise payable with respect to the BPH Business have been paid; (iii) all such Returns are accurate and complete in all material respects;
(iv) no adjustment relating to such Returns has been proposed in writing by any Tax authority; and (v) there are no Tax liens on any assets of the BPH Business, except with respect to Taxes being contested in good faith or Taxes for which
payment is not yet due and for which adequate reserves have been established on the Financial Statements. 
 (b)(i) There are no outstanding
waivers or agreements extending the statute of limitations for any period with respect to the assessment or collection of any Tax to which the BPH Business may be subject; and (ii) there are no requests for information from any relevant Tax
authorities currently outstanding that involve the Taxes of the BPH Business. 
 
SECTION 3.20 Insurance. All material assets, properties and risks of the BPH Business are, and for the past three years have been, covered by valid and, except for insurance policies that have expired under their
terms in the ordinary course, currently effective insurance policies or binders of insurance (including, without limitation, general liability insurance, property insurance and workers’ compensation insurance) issued in favor of the Seller, in
such types and amounts and covering such risks as are consistent with customary practices and standards of companies engaged in businesses and operations similar to those of the Seller. 
 
SECTION 3.21 Full Disclosure. (a) To the Knowledge of the Seller, there is no fact or facts pertaining to the Seller or the BPH Business which could have a Material Adverse Effect and which have not been
disclosed in this Agreement, the Purchase Disclosure Schedule, the Financial Statements, the Interim Financial Statement or otherwise disclosed to the Purchaser by the Seller in writing. 
  

 27 

Table of Contents

 (b) No representation or warranty of the Seller in this Agreement, nor any statement or certificate
furnished or to be furnished to the Purchaser pursuant to this Agreement, contains or will contain any untrue statement of a material fact, or omits or will omit to state a material fact necessary to make the statements contained herein or therein
not misleading. 
 
SECTION 3.22 Brokers. Other than Legg Mason Wood Walker Incorporated, no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the
transactions contemplated by this Agreement or the Ancillary Agreements based upon arrangements made by or on behalf of the Seller. The Seller is solely responsible for any amounts payable to Legg Mason Wood Walker Incorporated. 
 
ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES 
 OF THE PURCHASER 
 As an inducement to the Seller to enter into this Agreement,
the Purchaser hereby represents and warrants to the Seller as follows: 
 
SECTION 4.01 Organization and Authority of the Purchaser. The Purchaser is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all necessary
corporate power and authority to enter into this Agreement and the Ancillary Agreements to which it is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The entering
into of this Agreement by the Purchaser and the execution and delivery by the Purchaser of the Ancillary Agreements to which the Purchaser is a party, the performance by the Purchaser of its obligations hereunder and thereunder and the consummation
by the Purchaser of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of the Purchaser. This Agreement has been duly entered into by the Purchaser, and upon their execution, the
Ancillary Agreements to which the Purchaser is a party shall have been duly executed and delivered by the Purchaser, and this Agreement constitutes, and (assuming due authorization, execution and delivery by the Seller) upon their execution the
Ancillary Agreements to which the Purchaser is a party shall constitute, legal, valid and binding obligations of the Purchaser, enforceable against the Purchaser in accordance with their respective terms, subject to (i) applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance, and other laws relating to or affecting the rights of creditors generally (including, without limitation, fraudulent conveyance laws) and (ii) the exercise of judicial discretion in
accordance with general principles of equity, regardless of whether such enforceability is considered in a proceeding at law or in equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the
possible unavailability of specific performance, or injunctive relief. 
 
SECTION 4.02 No Conflict. Assuming compliance with the notification requirements of the HSR Act, the entering into and performance by the Purchaser of this Agreement and the execution, delivery and performance by
the Purchaser of the Ancillary Agreements to which the Purchaser is a party do not and will not (a) violate, conflict with or result in the breach of any provision of the Certificate of Incorporation or By-laws of the Purchaser,
(b) conflict with or violate any Law or Governmental Order applicable to the Purchaser or (c) conflict 

  

 28 

Table of Contents

 
with, or result in any breach of, constitute a default (or event which with the giving of notice or lapse of time, or both, would become a default) under,
require any consent under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or cancellation of, any note, bond, mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise or
other instrument or arrangement to which the Purchaser is a party, which would adversely affect the ability of the Purchaser to carry out its obligations under, and to consummate the transactions contemplated by, this Agreement or by the Ancillary
Agreements. 
 
SECTION 4.03 Governmental Consents and Approvals. The performance by the Purchaser of this Agreement and the execution, delivery and performance by the Purchaser of each Ancillary Agreement to which the Purchaser
is a party do not and will not require any consent, approval, authorization or other order of, action by, filing with, or notification to any Governmental Authority, except the notification requirements of the HSR Act. 
 
SECTION 4.04 Litigation. No Action by or against the Purchaser is pending or, to the knowledge of the Purchaser after due inquiry, threatened, which could affect the legality, validity or enforceability of this
Agreement, any Ancillary Agreement or the consummation of the transactions contemplated hereby or thereby. The Purchaser is not subject to any Government Order (nor, to the knowledge of the Purchaser after due inquiry, are there any such
Governmental Orders threatened to be imposed by any Governmental Authority) which could affect the legality, validity or enforceability of this Agreement, any Ancillary Agreement or the consummation of the transactions contemplated hereby or
thereby. 
 
SECTION 4.05 Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon
arrangements made by or on behalf of the Purchaser. 
 
ARTICLE V 
 ADDITIONAL AGREEMENTS 
 
SECTION 5.01 Conduct of BPH Business Prior to the Closing. (a) The Seller covenants and agrees that, except as described in Section 5.01(a) of the Purchase Disclosure Schedule, between the date hereof
and the time of the Closing, the Seller shall not conduct the BPH Business other than in the ordinary course and consistent with the Seller’s prior practice. Without limiting the generality of the foregoing, except as described in
Section 5.01(a) of the Purchase Disclosure Schedule, the Seller shall (as it relates to the BPH Business) (i) continue its pricing and purchasing policies, in accordance with past practice; (ii) use its best efforts to
(A) preserve intact the business organization of the BPH Business, (B) continue in full force and effect without material modification all existing policies or binders of insurance currently maintained in respect of the BPH Business and
(C) preserve its current relationships with customers, suppliers and other persons with which it has significant business relationships; (iii) not cancel, suspend or delay the funding of any development programs with respect to the
Products; (iv) maintain the level, mix and quality of the Inventories consistent with past practice; (v) not grant any rebates, discounts, advances or allowances to any customers of the BPH Business, except in the ordinary course of
business and consistent with its past practice and (vi) not engage in any practice, take any action, fail to take any action or enter into any transaction which could cause any representation or 

  

 29 

Table of Contents

 
warranty of the Seller to be untrue or result in a breach of any covenant made by the Seller in this Agreement. 
 (b) Except as described in Section 5.01(b) of the Purchase Disclosure Schedule, the Seller covenants and agrees that, between the date hereof and
the time of the Closing, without the prior written consent of the Purchaser, the Seller will not do any of the things enumerated in the second sentence of Section 3.07 (including, without limitation, clauses (i) through
(xvii) thereof). 
 
SECTION 5.02 Access to Information. (a) From the date hereof until the Closing, upon reasonable notice, the Seller shall cause its officers, directors, employees, agents, representatives, accountants and
counsel to: (i) afford the officers, employees, agents, accountants, counsel, financing sources and representatives of the Purchaser reasonable access, during normal business hours, to the offices, properties, plants, other facilities, books
and records of the Seller relating to the BPH Business, and to those officers, directors, employees, agents, accountants and counsel of the Seller who have any knowledge relating to the BPH Business and (ii) furnish to the officers, employees,
agents, accountants, counsel, financing sources and representatives of the Purchaser such additional financial and operating data and other information regarding the assets, properties, liabilities and goodwill of the BPH Business (or legible copies
thereof) as the Purchaser may from time to time reasonably request. 
 (b) In order to facilitate the resolution of any claims made against
or incurred by the Seller prior to the Closing, for a period of five years after the Closing, the Purchaser shall (i) retain the books and records relating to the BPH Business relating to periods prior to the Closing in a manner reasonably
consistent with the prior practice of the Seller and (ii) upon reasonable notice, afford the officers, employees, agents and representatives of the Seller reasonable access (including the right to make, at the Seller’s expense,
photocopies), during normal business hours, to such books and records. 
 (c) In order to facilitate the resolution of any claims made by or
against or incurred by the Purchaser after the Closing or for any other reasonable purpose, for a period of five years following the Closing, the Seller shall (i) retain the books and records of the Seller which relate to the BPH Business and
its operations for periods prior to the Closing and which shall not otherwise have been delivered to the Purchaser and (ii) upon reasonable notice, afford the officers, employees, agents and representatives of the Purchaser reasonable access
(including the right to make photocopies, at the expense of the Purchaser), during normal business hours, to such books and records. 
 (d)
Each of the Seller and the Purchaser shall provide each other with such cooperation and information as either of them reasonably may request of another in filing any Return, amended return or claim for refund, determining a liability for Taxes or a
right to a refund of Taxes or participating in or conducting any audit or other proceeding in respect of Taxes. Such cooperation and information shall include providing copies of relevant Returns or portions thereof, together with accompanying
schedules and related work papers and documents relating to rulings or other determinations by Tax authorities. Each such party shall make its employees available on a mutually convenient basis to provide explanations of any documents or information
provided hereunder. Any information obtained under this Section 5.02(d) shall be kept confidential, except 

  

 30 

Table of Contents

 
as may be otherwise necessary in connection with the filing of Returns or claims for refund or in conducting an audit or other proceeding. 
 
SECTION 5.03 Confidentiality. The Seller agrees to, and shall cause its agents, representatives, Affiliates, employees, officers and directors to: (a) treat and hold as confidential (and not disclose or
provide access to any Person to) all information relating to Trade Secrets, Copyrights, processes, Patent and Trademark applications, product development, price, customer and supplier lists, pricing and marketing plans, policies and strategies,
details of client and consultant contracts, operations methods, product development techniques, business acquisition plans and all other confidential or proprietary information with respect to the BPH Business, (b) in the event that the Seller
or any such agent, representative, Affiliate, employee, officer or director becomes legally compelled to disclose any such information, provide the Purchaser with prompt written notice of such requirement so that the Purchaser may seek a protective
order or other remedy or waive compliance with this Section 5.03, (c) in the event that such protective order or other remedy is not obtained, or the Purchaser waives compliance with this Section 5.03, furnish only that portion of
such confidential information which is legally required to be provided and exercise its best efforts to obtain assurances that confidential treatment will be accorded such information, and (d) promptly furnish (prior to, at, or as soon as
practicable following, the Closing) to the Purchaser any and all copies (in whatever form or medium) of all such confidential information then in the possession of the Seller or any of its agents, representatives, Affiliates, employees, officers and
directors and, except as otherwise required by Section 5.02(c), destroy any and all additional copies then in the possession of the Seller or any of its agents, representatives, Affiliates, employees, officers and directors of such information
and of any analyses, compilations, studies or other documents prepared, in whole or in part, on the basis thereof; provided, however, that this sentence shall not apply to any information that, at the time of disclosure, is available
publicly and was not disclosed in breach of this Agreement by the Seller, its agents, representatives, Affiliates, employees, officers or directors; and provided further that, with respect to Intellectual Property, specific information
shall not be deemed to be within the foregoing exception merely because it is embraced in general disclosures in the public domain. In addition, with respect to Intellectual Property, any combination of features shall not be deemed to be within the
foregoing exception merely because the individual features are in the public domain unless the combination itself and its principle of operation are in the public domain. The Seller agrees and acknowledges that remedies at law for any breach of its
obligations under this Section 5.03 are inadequate and that in addition thereto the Purchaser shall be entitled to seek equitable relief, including injunction and specific performance, in the event of any such breach. 
 
SECTION 5.04 Regulatory and Other Authorizations; Notices and Consents. (a) The Seller shall use all commercially reasonable efforts to obtain all authorizations, consents, orders and approvals of all
Governmental Authorities that may be or become necessary for the performance of its obligations pursuant to this Agreement or its execution and delivery of, and the performance of its obligations pursuant to, the Ancillary Agreements and will
cooperate fully with the Purchaser in promptly seeking to obtain all such authorizations, consents, orders and approvals. Each party hereto agrees to make an appropriate filing, if necessary, pursuant to the HSR Act with respect to the transactions
contemplated by this Agreement within five Business Days of the date hereof and to supply as promptly as practicable to the appropriate Governmental Authorities any additional information and documentary material that may be requested pursuant to
the HSR Act. 
  

 31 

Table of Contents

 (b) The Seller shall give promptly such notices to third parties and use all commercially reasonable
efforts to obtain such third party consents as the Purchaser may in its sole discretion deem necessary or desirable in connection with the transactions contemplated by this Agreement. 
 (c) The Purchaser shall cooperate and use all reasonable efforts to assist the Seller in giving such notices and obtaining such consents;
provided, however, that the Purchaser shall have no obligation to give any guarantee or other consideration of any nature in connection with any such notice, consent or to consent to any change in the terms of any agreement or
arrangement which the Purchaser in its reasonable discretion may deem adverse to the interests of the Purchaser or the BPH Business. 
 (d)
The Seller and the Purchaser agree that, in the event that any consent, approval or authorization necessary or desirable to preserve for the BPH Business any right or benefit under any lease, license, contract, commitment or other agreement or
arrangement to which the Seller is a party is not obtained prior to the Closing, the Seller will, subsequent to the Closing, cooperate with the Purchaser in attempting to obtain such consent, approval or authorization as promptly thereafter as
practicable. If such consent, approval or authorization cannot be obtained, the Seller shall use its best efforts to provide the Purchaser with the rights and benefits of the affected lease, license, contract, commitment or other agreement or
arrangement for the term of such lease, license, contract or other agreement or arrangement, and, if the Seller provides such rights and benefits, the Purchaser shall assume the obligations and burdens thereunder to the extent that such obligations
and burdens constitute Assumed Liabilities. 
 
SECTION 5.05 Notice of Developments. Prior to the Closing, the Seller shall promptly notify the Purchaser in writing of (a) all events, circumstances, facts and occurrences arising subsequent to the date of
this Agreement which could result in any breach of a representation or warranty or covenant of the Seller in this Agreement or which could have the effect of making any representation or warranty of the Seller in this Agreement untrue or incorrect
in any respect and (b) all other material developments affecting the assets, Liabilities, business, financial condition, operations, results of operations, customer or supplier relations, projections or prospects of the BPH Business.

 
SECTION 5.06 Non-Competition. (a) For a period of five years after the Closing or, in the European Union, for a period of three years after the Closing (in either case, the “Restricted
Period”), the Seller shall not engage, directly or indirectly, in any business anywhere in the world that manufactures, markets, distributes, sells and/or researches and develops products or services of the kind manufactured, marketed,
distributed, sold and/or researched and developed by the BPH Business as of the Closing Date or, without the prior written consent of the Purchaser, directly or indirectly, own an interest in, manage, operate, join, control, lend money or render
financial or other assistance to or participate in or be connected with, as an officer, employee, partner, stockholder, consultant or otherwise, any Person that competes with the BPH Business in the manufacture, marketing, distribution, sale and/or
research and development of products or services of the kind manufactured, marketed, distributed, sold and/or researched and developed by the BPH Business as of the Closing Date; provided, however, that, for the purposes of this
Section 5.06, ownership of securities having no more than five percent of the outstanding voting power of any competitor which are listed on any national securities exchange shall not be deemed to be in 

  

 32 

Table of Contents

 
violation of this Section 5.06 as long as the Person owning such securities has no other connection or relationship with such competitor. 
 (b) As a separate and independent covenant, the Seller agrees with the Purchaser that, for a period of five years following the Closing, the Seller will
not in any way, directly or indirectly, for the purpose of conducting or engaging in any business that manufactures, markets, distributes, sells and/or researches and develops products or services of the kind manufactured, marketed, distributed,
sold and/or researched and developed by the BPH Business as of the Closing Date, call upon, solicit, advise or otherwise do, or attempt to do, business with any Person who was a customer of the BPH Business at any time prior to the Closing Date or
take away or interfere or attempt to interfere with any custom, trade, business or patronage of the BPH Business. 
 (c) The Restricted
Period shall be extended by the length of any period during which the Seller is in breach of the terms of this Section 5.06. 
 (d) The
Seller acknowledges that the covenants of the Seller set forth in this Section 5.06 are an essential element of this Agreement and that, but for the agreement of the Seller to comply with these covenants, the Purchaser would not have entered
into this Agreement. The Seller acknowledges that this Section 5.06 constitutes an independent covenant and shall not be affected by performance or nonperformance of any other provision of this Agreement by the Purchaser. The Seller has
independently consulted with its counsel and after such consultation agrees that the covenants set forth in this Section 5.06 are reasonable and proper. 
 
SECTION 5.07 Excluded Liabilities. The Seller shall pay and discharge the Excluded Liabilities as and when the same become due and payable. 
 
SECTION 5.08 Bulk Transfer Laws. The Purchaser hereby waives compliance by the Seller with any applicable bulk sale or bulk transfer laws of any jurisdiction in connection with the sale of the BPH Assets to the
Purchaser (other than any obligations with respect to the application of the proceeds therefrom). Pursuant to Article VII, the Seller has agreed to indemnify the Purchaser against any and all liabilities (including, but not limited to, any
liabilities for Taxes of Seller as a transferee or otherwise) which may be asserted by third parties against the Purchaser as a result of the Seller’s noncompliance with any such law. 
 
SECTION 5.09 Transition Services. Following the Closing Date, the Seller shall provide, or cause to be provided, to the BPH Business those services that are currently provided by the Seller and its Affiliates to
the BPH Business, at cost, all as more fully set forth in a transition services agreement substantially in the form attached hereto as Exhibit 5.09 (the “Transition Services Agreement”) to be entered into by the Seller and the
Purchaser as of the Closing Date. Not less that ten days following the date hereof, the Seller shall provide to the Purchaser a comprehensive list of all services currently provided by the Seller and its Affiliates to the BPH Business and a list of
the personnel of the Seller and its Affiliates performing services for the BPH Business. Thereafter, the Purchaser shall determine, at its discretion, which services and personnel it will require to be provided pursuant to the terms of the
Transition Services Agreement and shall complete Exhibit A and Exhibit B of the Transition Services Agreement accordingly. 
  

 33 

Table of Contents

 
SECTION 5.10 Public Announcements. No press release related to this Agreement or the transactions contemplated herein, or any other announcement or communication relating to the subject matter of any Acquisition
Document shall be issued or made without the consent of the other party, except any public disclosure which the Seller or the Purchaser in its good faith judgment believes is required by Law (in which case the party making the disclosure will use
its commercially reasonable efforts to consult with the other party prior to making any such disclosure). 
 
SECTION 5.11 License. Subject to the terms and conditions herein, the Purchaser hereby grants (to the extent permitted in the Seller IP Agreements) to the Seller a royalty-free, worldwide, non-transferable
(except as provided below) right and license to use the Software (as it exists as of the Closing Date) utilized in the Products in connection with the Seller’s business other than any business that may reasonably compete with the BPH Business
in the manufacture, marketing, distribution, sale and/or research and development of products or services of the kind manufactured, marketed, distributed, sold and/or researched and developed by the BPH Business as of the Closing Date. The Seller
may sublicense the right and license granted hereunder to third parties, subject to the limitations contained herein, and the Seller agrees that it shall be solely responsible for any actions of its sublicensees in contravention of such limitations.

 
SECTION 5.12 Stockholder Meeting; Proxy Materials. (a) As promptly as practicable after the execution of this Agreement, the Seller shall (i) take all action necessary to duly call, give notice of,
convene and hold a meeting of its stockholders (which may be held in conjunction with its 2007 annual stockholder meeting) for the purpose of obtaining the Requisite Stockholder Approval (such meeting, the “Seller Stockholder
Meeting”), (ii) include in the Proxy Statement the recommendation of the Board of Directors of the Seller that the stockholders of the Seller approve the consummation of the transactions contemplated by this Agreement (the
“Recommendation”) and (iii) use its reasonable best efforts to take all action necessary to obtain the Requisite Stockholder Approval, including postponing or adjourning the Seller Stockholder Meeting to obtain a quorum or to
solicit additional proxies or calling, giving notice of, convening and holding additional stockholders’ meetings, it being understood by the Purchaser that the outcome of any vote taken at the Seller Stockholder Meeting shall not in and of
itself be dispositive as to whether the Seller has complied with its obligations under this clause (iii). Neither the Board of Directors of the Seller nor any committee thereof shall directly or indirectly (x) withdraw, modify or qualify, or
publicly propose to withdraw, modify or qualify, the Recommendation or (y) take any other action or make any other public statement in connection with the Seller Stockholder Meeting inconsistent with such Recommendation. 
 (b) In connection with the Seller Stockholder Meeting, the Company will (i) as promptly as reasonably practicable, prepare and file with the
Securities and Exchange Commission the proxy statement (such proxy statement, as amended or supplemented, being referred to herein as the “Proxy Statement”), (ii) thereafter mail to its stockholders as promptly as reasonably
practicable, the Proxy Statement and all other customary proxy or other materials for meetings such as the Seller Stockholder Meeting, (iii) to the extent required by applicable Law, as promptly as reasonably practicable prepare, file and
distribute to the stockholders of the Seller any supplement or amendment to the Proxy Statement if any event shall occur which requires such action at any time prior to the Seller Stockholder Meeting and (iv) otherwise use its reasonable best
efforts to comply with all requirements of Law applicable to the Seller Stockholder Meeting. The 

  

 34 

Table of Contents

 
Seller will provide the Purchaser with a reasonable opportunity to review and comment upon the Proxy Statement, or any amendments or supplements thereto,
prior to filing any such documents with the Securities and Exchange Commission. 
 
ARTICLE VI 
 CONDITIONS TO CLOSING 
 
SECTION 6.01 Mutual Conditions to the Closing. The respective obligations of the Seller and the Purchaser to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or
written waiver, at or prior to the Closing, of each of the following conditions: 
 (a) HSR Act. Any waiting period
(and any extension thereof) under the HSR Act applicable to the purchase of the BPH Assets contemplated by this Agreement shall have expired or shall have been terminated; 
 (b) Other Governmental Approvals. Any waiting period required under any applicable Laws (other than the HSR Act) shall have expired
or shall have been terminated, and the Seller and the Purchaser shall have received, each in form and substance satisfactory to the Purchaser, all consents, approvals and authorizations of all Governmental Authorities; and 
 (c) No Injunction. No court of competent jurisdiction or other competent Governmental Authority shall have issued an order, decree
or injunction or taken any other action restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement. 
 (d) Stockholder Approval. The Seller shall have obtained the Requisite Stockholder Approval. 
 
SECTION 6.02 Conditions to Obligations of the Seller. In addition to Section 6.01, the obligations of the Seller to consummate the transactions contemplated by this Agreement shall be subject to the
fulfillment or written waiver, at or prior to the Closing, of each of the following conditions: 
 (a) Representations,
Warranties and Covenants. The representations and warranties of the Purchaser contained in this Agreement shall have been true and correct in all material respects when made and shall be true and correct in all material respects as of the
Closing, with the same force and effect as if made as of the Closing Date (other than such representations and warranties that are made as of another date, which shall be true and correct in all material respects as of such date), the covenants and
agreements contained in this Agreement to be complied with by the Purchaser on or before the Closing Date shall have been complied with in all material respects, and the Seller shall have received a certificate from the Purchaser to such effect
signed by a duly authorized officer thereof; and 
  

 35 

Table of Contents

 (b) Ancillary Agreements. The Purchaser shall have executed and delivered to the
Seller each of the Ancillary Agreements to which it is a party. 
 
SECTION 6.03 Conditions to Obligations of the Purchaser. In addition to Section 6.01, the obligations of the Purchaser to consummate the transactions contemplated by this Agreement shall be subject to the
fulfillment or written waiver, at or prior to the Closing, of each of the following conditions: 
 (a) Representations,
Warranties and Covenants. The representations and warranties of the Seller contained in this Agreement (i) that are not qualified by “materiality” or “Material Adverse Effect” shall have been true and correct in all
material respects when made and shall be true and correct in all material respects as of the Closing Date with the same force and effect as if made as of the Closing Date and (ii) that are qualified by “materiality” or Material
Adverse Effect” shall have been true and correct when made and shall be true and correct as of the Closing Date with the same force and effect as if made as of the Closing Date, (other than such representations and warranties that are made as
of another date, which shall be true and correct in all material respects as of such date), the covenants and agreements contained in this Agreement to be complied with by the Seller on or before the Closing Date shall have been complied with in all
material respects, and the Purchaser shall have received a certificate of the Seller to such effect signed by a duly authorized officer thereof; 
 (b) No Proceeding or Litigation. No Action shall have been commenced or threatened by or before any Governmental Authority against either the Seller or the Purchaser, seeking to restrain or materially and
adversely alter the transactions contemplated by this Agreement which, in the reasonable, good faith determination of the Purchaser, is likely to render it impossible or unlawful to consummate such transactions or which could have a Material Adverse
Effect or otherwise render inadvisable, in the sole discretion of the Purchaser, the consummation of the transactions contemplated by this Agreement; 
 (c) Consents and Approvals. Any waiting period required under any applicable Laws (other than the HSR Act) shall have expired or shall have terminated, and the Purchaser and the Seller shall have received, each
in form and substance reasonably satisfactory to the Purchaser, all authorizations, consents, orders and approvals of all Governmental Authorities and all third party consents which the Purchaser in its sole discretion deems necessary for the
consummation of the transactions contemplated by this Agreement and the Ancillary Agreements, including, without limitation, all third party consents required under any BPH Material Contracts; 
 (d) No Material Adverse Effect. No event or events shall have occurred, or be reasonably likely to occur, which, individually or in
the aggregate, have, or could have, a Material Adverse Effect; 
 (e) Ancillary Agreements. The Seller shall have
executed and delivered to the Purchaser each of the Ancillary Agreements to which it is a party; 
  

 36 

Table of Contents

 (f) Distribution Agreement. The Distribution Agreement shall have been terminated
in accordance with Section 8.03 and Section 8.04 thereof; and 
 (g) AMS Settlement and License Agreement
Payments. The Seller shall have made all payments required or permitted to be made by it in respect of all royalties payable by or on behalf of the Seller under the AMS Settlement and License Agreement, including Section 3.03 thereof.

 
ARTICLE VII 
 INDEMNIFICATION 
 
SECTION 7.01 Survival of Representations and Warranties. 
 (a) The representations and warranties of the
Seller contained in this Agreement and the Ancillary Agreements shall survive the Closing until 18 months after the Closing Date; provided, however, that (i) the representations and warranties made pursuant to Sections 3.01, 3.16
and 3.22 shall survive indefinitely, (ii) the representations and warranties dealing with Tax matters shall survive the close of business on the 120th day following the expiration of the applicable statute of limitations with respect to the Tax
liabilities in question (giving effect to any waiver, mitigation or extension thereof), (iii) insofar as any claim is made by the Purchaser for the breach of any representation or warranty of the Seller contained herein, which claim arises out
of allegations of personal injury or property damage suffered by any third party on or prior to the Closing Date or attributable to products or Inventory sold or shipped on or prior to the Closing Date, such representations and warranties shall, for
purposes of such claim by the Purchaser, survive until thirty calendar days after the expiration of the applicable statute of limitations governing such claims, and (iv) insofar as any claim is made by the Purchaser for the breach of any
representation or warranty of the Seller contained herein relating to environmental matters, such representations and warranties shall, for purposes of such claims by the Purchaser, survive the Closing until the tenth anniversary of the Closing
Date. If written notice of a claim has been given prior to the expiration of the applicable representations and warranties by the Purchaser to the Seller, then the relevant representations and warranties shall survive as to such claim, until such
claim has been finally resolved. 
 (b) The representations and warranties of the Purchaser contained in this Agreement and the Ancillary
Agreements shall survive the Closing until 18 months after the Closing Date; provided, however, that the representations and warranties made pursuant to Sections 4.01 and 4.05 shall survive indefinitely. If written notice of a claim
has been given prior to the expiration of the applicable representations and warranties by the Seller to the Purchaser, then the relevant representations and warranties shall survive as to such claim, until such claim has been finally resolved.

 
SECTION 7.02 Indemnification by the Seller. The Purchaser and its Affiliates, officers, directors, employees, agents, successors and assigns (each a “Purchaser Indemnified Party”) shall be
indemnified and held harmless by the Seller for and against any and all Liabilities, losses, diminution in value, damages, claims, costs and expenses, interest, awards, judgments and 

  

 37 

Table of Contents

 
penalties (including, without limitation, attorneys’ and consultants’ fees and expenses) actually suffered or incurred by them (including, without
limitation, any Action brought or otherwise initiated by any of them) (hereinafter a “Loss”), arising out of or resulting from: 
 (a) the breach of any representation or warranty made by the Seller contained in the Acquisition Documents (it being understood that such representations and warranties shall be interpreted without giving effect to
(i) any limitations or qualifications as to “materiality” (including the word “material”) or “Material Adverse Effect” set forth therein or (ii) any exception set forth in the Purchase Disclosure Schedule to
the extent that any such exception constitutes an Excluded Liability); 
 (b) the breach of any covenant or agreement by the
Seller contained in the Acquisition Documents; 
 (c) Liabilities arising from or related to any failure to comply with laws
relating to bulk transfers or bulk sales with respect to the transactions contemplated by this Agreement (notwithstanding the waiver contained in Section 5.08); 
 (d) the Excluded Liabilities; and 
 (e) the Purchaser Amounts. 
 To the extent that the Seller’s undertakings set forth in this
Section 7.02 may be unenforceable, the Seller shall contribute the maximum amount that it is permitted to contribute under applicable Law to the payment and satisfaction of all Losses incurred by the Purchaser Indemnified Parties. 

SECTION 7.03 Indemnification by the Purchaser. The Seller and its Affiliates, officers, directors, employees, agents, successors and assigns (each a “Seller Indemnified Party”) shall be
indemnified and held harmless by the Purchaser for and against any and all Losses, arising out of or resulting from: 
 (a)
the breach of any representation or warranty made by the Purchaser contained in the Acquisition Documents; 
 (b) the breach
of any covenant or agreement by the Purchaser contained in the Acquisition Documents; and 
 (c) the Assumed Liabilities.

 To the extent that the Purchaser’s undertakings set forth in this Section 7.03 may be unenforceable, the Purchaser shall
contribute the maximum amount that it is permitted to contribute under applicable Law to the payment and satisfaction of all Losses incurred by the Seller Indemnified Parties. 
 
SECTION 7.04 Enforcing Claims Under Indemnity. Unless otherwise provided in this Article VII, an Indemnified Party shall give the Indemnifying Party notice of any matter which an Indemnified Party has determined
has given or could give rise to a right of indemnification 

  

 38 

Table of Contents

 
under this Agreement, within sixty (60) days of such determination, stating the amount of the Loss, if known, and method of computation thereof, and
containing a reference to the Section of this Agreement in respect of which it elects to seek and recover indemnification. The obligations and liabilities of the Indemnifying Party under this Article VII with respect to Losses arising from Claims of
any third party which are subject to the indemnification provided for in this Article VII (“Third Party Claims”) shall be governed by and be contingent upon the following additional terms and conditions: if an Indemnified Party
shall receive notice of any Third Party Claim, the Indemnified Party shall give the Indemnifying Party notice of such Third Party Claim within thirty (30) days of the receipt by the Indemnified Party of such notice; provided,
however, that the failure to provide such notice shall not release the Indemnifying Party from any of its obligations under this Article VII except to the extent that the Indemnifying Party is materially prejudiced by such failure and shall
not relieve the Indemnifying Party from any other obligation or liability that it may have to any Indemnified Party otherwise than under this Article VII. The Indemnifying Party shall be entitled to assume and control the defense of such Third Party
Claim at its expense and through counsel of its choice if it acknowledges its obligation to indemnify the Indemnified Party in respect of such Third Party Claim and of its intention to assume and control the defense thereof within five (5) days
of the receipt of such notice from the Indemnified Party; provided, however, that if there exists or is reasonably likely to exist a conflict of interest that would make it inappropriate in the judgment of the Indemnified Party in its
reasonable discretion for the same counsel to represent both the Indemnified Party and the Indemnifying Party, then the Indemnified Party shall be entitled to retain its own counsel in each jurisdiction for which the Indemnified Party determines
counsel is required, at the expense of the Indemnifying Party; provided further that, in respect of any matter relating to Intellectual Property, the Purchaser shall be entitled to retain its own counsel and fully control the defense
of, and prosecution of counterclaims related to, any such Third Party Claim. In the event that the Indemnifying Party exercises the right to undertake any such defense against any such Third Party Claim as provided above, the Indemnified Party shall
cooperate with the Indemnifying Party in such defense and make available to the Indemnifying Party, at the Indemnifying Party’s expense, all witnesses, pertinent records, materials and information in the Indemnified Party’s possession or
under the Indemnified Party’s control relating thereto as is reasonably required by the Indemnifying Party. Similarly, in the event the Indemnified Party is, directly or indirectly, conducting the defense against any such Third Party Claim, the
Indemnifying Party shall cooperate with the Indemnified Party in such defense and make available to the Indemnified Party, at the Indemnifying Party’s expense, all such witnesses, records, materials and information in the Indemnifying
Party’s possession or under the Indemnifying Party’s control relating thereto as is reasonably required by the Indemnified Party; provided, however, that the foregoing expenses and costs when added to the financial
obligations of the Indemnifying Party under this Section 7.04 shall not exceed $15,000,000 with respect to indemnification claims pursuant to Section 7.02(e). Neither the Indemnifying Party nor the Indemnified Party may settle any such
Third Party Claim without the prior written consent of the other party, unless such settlement (a) does not subject the other party to any monetary liability (other than any monetary liability the Indemnifying Party may have to the Indemnified
Party under the terms of this Agreement, including Sections 7.02 and 7.03) or impose any restriction on the other party’s future activity or conduct and (b) includes a complete, unconditional release of the other party from all liabilities
with respect to such Third Party Claim. The Indemnifying Party or the Indemnified Party, as the case may be, shall keep the other party reasonably apprised of material developments related to the settlement of any such 

  

 39 

Table of Contents

 
Third Party Claim, including providing the other party with copies of correspondence with third parties that the Indemnifying or Indemnified Party, as the
case may be, determines is material to the settlement of such Third Party Claim, and shall provide the other party with advance notice of any such settlement. Nothing contained herein shall be construed as to release the Indemnified Party from its
obligations under any other provision contained in this Article VII. 
 
SECTION 7.05 Limits on Indemnification. Notwithstanding anything to the contrary contained in this Agreement: (a) an Indemnifying Party shall not be liable for any claim for indemnification pursuant to
Sections 7.02 or 7.03, unless and until the aggregate amount of indemnifiable Losses which may be recovered from the Indemnifying Party equals or exceeds $500,000, after which the Indemnifying Party shall be liable only for those Losses in excess of
$500,000; and (b) the maximum amount of indemnifiable Losses which may be recovered from an Indemnified Party arising out of or resulting from the causes set forth in Section 7.02(a) or 7.03(a), as the case may be, shall be an amount equal
to the Purchase Price; provided, that the limitations in (a) shall not apply to Purchaser Amounts, Conditional Amounts or representations and warranties made pursuant to Section 3.19 and the limitations in (b) shall not apply
to representations and warranties made pursuant to Section 3.19; provided further that the maximum amount of indemnifiable Losses which the Purchaser may recover from the Seller solely under Section 7.02(e) shall be
$15,000,000. Notwithstanding anything to the contrary contained in this agreement, the foregoing limitations shall not apply in respect of any claim for indemnification arising out of or resulting from fraud or intentional misrepresentation on the
part of the Indemnifying Party. 
 
SECTION 7.06 Treatment of Indemnity Payments. The Seller and the Purchaser agree (to the extent permitted by applicable Law) to treat all payments made by either party to or for the benefit of the other party
under any indemnity provisions of this Agreement and for any misrepresentations or breach of warranties or covenants as adjustments to the Purchase Price for Tax purposes and that such treatment shall govern for all purposes hereof. 
 
SECTION 7.07 Set-off Rights. In addition to any other rights and remedies it may have under this Agreement and applicable Law, but subject to the limitations set forth in Sections 2.08 and 7.05, the Purchaser may
exercise a right of set-off against the Second Payment or the Third Payment as a result of any Losses arising out of or resulting from the matters set forth in clauses (a) through (d) of Section 7.02. The Purchaser shall promptly
notify the Seller of any such set-off; provided, however, that the Purchaser’s failure to so notify the Seller shall not affect the validity of any such set-off. 
 
ARTICLE VIII 
 TERMINATION 
 
SECTION 8.01 Termination. This Agreement may be terminated at any time prior to the Closing: 
 (a) by the Purchaser if, between the date hereof and the Closing: (i) an event or condition occurs that has resulted in a Material Adverse Effect, (ii) any representations and warranties of the Seller contained in this Agreement
(1) that are not qualified by 

  

 40 

Table of Contents

 
“materiality” or “Material Adverse Effect” shall not have been true and correct in all material respects when made or (2) that are
qualified by “materiality” or “Material Adverse Effect” shall not have been true and correct when made, (iii) the Seller shall not have complied in all material respects with the covenants or agreements contained in this
Agreement to be complied with by it or (iv) the Seller makes a general assignment for the benefit of creditors, or any proceeding shall be instituted by or against the Seller seeking to adjudicate any of them a bankrupt or insolvent, or seeking
liquidation, winding up or reorganization, arrangement, adjustment, protection, relief or composition of its debts under any Law relating to bankruptcy, insolvency or reorganization; 
 (b) by either the Seller or the Purchaser if the Closing shall not have occurred by six months after the date hereof; provided,
however, that the right to terminate this Agreement under this Section 8.01(b) shall not be available to any party whose failure to fulfill any obligation under this Agreement shall have been the cause of, or shall have resulted in, the
failure of the Closing to occur on or prior to such date; 
 (c) by either the Purchaser or the Seller in the event that any
Governmental Authority shall have issued an order, decree or ruling or taken any other action restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement and such order, decree, ruling or other action shall have
become final and nonappealable; 
 (d) by either the Purchaser or the Seller in the event that the Requisite Stockholder
Approval is not obtained at the Seller Stockholder Meeting; 
 (e) by the Seller, if the Requisite Stockholder Approval is
obtained at the Seller Stockholder Meeting and Closing has not occurred within sixty (60) days of the Seller Stockholder Meeting; provided, however, that the right to terminate this Agreement under this Section 8.01(e) shall
not be available to the Seller if the failure of the Closing to occur on or prior to such date shall have been caused by, or shall have resulted from, any action or inaction of the Seller; or 
 (f) by the mutual written consent of the Seller and the Purchaser. 
 
SECTION 8.02 Effect of Termination. In the event of termination of this Agreement as provided in Section 8.01, this Agreement shall forthwith become void and there shall be no liability on the part of either
party hereto except (a) as set forth in Sections 5.03 and 8.03 and Article IX and (b) that nothing herein shall relieve either party from liability for any breach of this Agreement. 
 SECTION 8.03. Termination Fee. In the event of the termination of this Agreement as provided in Section 8.01(a) or 8.01(d) and at any time
following the date of this Agreement and prior to such termination a proposal is made by any Person (other than the Purchaser), and, in the case of the termination of this Agreement as provided in Section 8.01(d), publicly announced, involving
the acquisition of not less than a majority of the outstanding shares of voting stock of the Seller or all or any substantial portion of the assets of the Seller, then immediately upon the earlier to occur of (a) the Seller and any Person
entering into a definitive agreement with respect to such a proposal and (b) the closing of such a transaction by Seller with 

  

 41 

Table of Contents

 
any Person, the Seller shall pay to the Purchaser by wire transfer in immediately available funds to an account designated by the Purchaser a fee of $2.4
million. 
 
ARTICLE IX 
 MISCELLANEOUS 
 
SECTION 9.01 Expenses; Transfer Taxes. (a) Except as otherwise specified in this Agreement, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and
accountants, incurred in connection with this Agreement and the transactions contemplated by this Agreement shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred. 
 (b) Each of the Seller and the Purchaser shall pay one-half of (i) all filing and/or application fees required of the parties under the HSR Act and
(ii)all real property transfer or gains, sales, use, transfer, value added, goods and services, stock transfer, stamp taxes, and any similar Taxes which become payable in connection with the transactions contemplated hereby, and the parties shall
file such applications and documents as shall permit any such Tax to be assessed and paid on or prior to the Closing Date in accordance with any available pre-sale filing procedure. 
 
SECTION 9.02 Notices. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by
delivery in person, by an internationally recognized overnight courier service, by telecopy or registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address
for a party as shall be specified in a notice given in accordance with this Section 9.02): 
 (a) if to the Seller: 
 Celsion Corporation 
 10220-I Old Columbia Road 
 Columbia, Maryland 21046-1705 
 Attention: President and Chief Executive Officer 
 Facsimile No: (410) 290-5394 
 with a copy to: 
 Venable, Baetjer and Howard, LLP 
 Two Hopkins Plaza, Suite 1800 
 Baltimore, Maryland 21201 
 Attention: Michael J. Baader, Esq. 
 Facsimile: 410-244-7742 
  

 42 

Table of Contents

 (b) if to the Purchaser: 
 Boston Scientific Corporation 
 One Boston Scientific Place 
 Natick, MA 01760-1537 
 Attention: Lawrence C. Best, Chief Financial Officer 
 Facsimile No: (508) 650 8956 
 with a copy to: 
 Boston Scientific Corporation 
 One Boston Scientific Place 
 Natick, MA 01760-1537 
 Attention: General Counsel 
 Facsimile No: (508) 650 8956 
 with a copy to: 
 Shearman & Sterling 
 599 Lexington Avenue 
 New York, NY 10022 
 Attention: Clare O’Brien, Esq. 
 Facsimile No: (646) 848 8966 
 
SECTION 9.03 Headings. The descriptive headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of the Agreement. 
 
SECTION 9.04 Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall
nevertheless remain in full force and effect for so long as the economic or legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to any party. Upon such determination that any term or
other provision is invalid, illegal or incapable of being enforced, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that
the transactions contemplated by this Agreement are consummated as originally contemplated to the greatest extent possible. 
 
SECTION 9.05 Entire Agreement. This Agreement and the Ancillary Agreements constitute the entire agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede all prior
agreements and undertakings, both written and oral, between the parties with respect to the subject matter hereof and thereof. 
 
SECTION 9.06 Further Action. Each of the parties hereto shall use reasonable best efforts to take, or cause to be taken, all appropriate action, do or cause to be done all things necessary, proper or advisable
under applicable Law, and execute and deliver such documents and 

  

 43 

Table of Contents

 
other papers, as may be required to carry out the provisions of this Agreement and consummate and make effective the transactions contemplated by this
Agreement. 
 
SECTION 9.07 Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigned. Neither party may assign this Agreement without
the prior written consent of the other party, provided that the Purchaser may assign its rights and obligations under this Agreement without the approval of the Seller to an Affiliate of the Purchaser or to the purchaser of all or
substantially all of the BPH Assets. No assignment by either party permitted hereunder shall relieve the applicable party of its obligations under this Agreement. 
 
SECTION 9.08 Amendment. This Agreement may not be amended or modified except (a) by an instrument in writing signed by, or on behalf of, the Seller and the Purchaser or (b) by a waiver in accordance
with Section 9.10. 
 
SECTION 9.09 Governing Law and Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware. The parties unconditionally and irrevocably agree and consent to the
exclusive jurisdiction of the courts located in the State of Delaware and waive any objection with respect thereto, for the purpose of any action, suit or proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby, and further agree not to commence any such action, suit or proceeding except in any such court. 
 
SECTION 9.10 Waiver. Either party to this Agreement may (a) extend the time for the performance of any of the obligations or other acts of the other party, (b) waive any inaccuracies in the
representations and warranties of the other party contained herein or in any document delivered by the other party pursuant hereto or (c) waive compliance with any of the agreements of the other party or conditions to such party’s
obligations contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the party to be bound thereby. Any waiver of any term or condition shall not be construed as a waiver of any subsequent
breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Agreement. The failure of any party to assert any of its rights hereunder shall not constitute a waiver of any of such rights. All rights
and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available. 
 
SECTION 9.11 No Third Party Beneficiaries. Except for the provisions of Article VII relating to indemnified parties, this Agreement shall be binding upon and inure solely to the benefit of the parties hereto and
their permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever. 
 
SECTION 9.12 Agreement. All Schedules and Exhibits attached to this Agreement shall be deemed part of this Agreement and incorporated herein, as if fully set forth herein. 
 
SECTION 9.13 WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY 

  

 44 

Table of Contents

 
LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH OF THE
PARTIES HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND
(B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION
9.13. 
  

 45 

Table of Contents

 IN WITNESS WHEREOF, the Seller and the Purchaser have caused this Agreement to be executed as of the date
first written above by their respective officers thereunto duly authorized. 
  

			
	CELSION CORPORATION
		
	By:	 	 /s/ Michael H Tardugno

	Name:	 	Michael H Tardugno
	Title:	 	President and Chief Executive Officer
	
	BOSTON SCIENTIFIC CORPORATION
		
	By:	 	 /s/ Lawrence C. Best

	Name:	 	Lawrence C. Best
	Title:	 	 Executive Vice President-Finance and
 Administration
and Chief Financial Officer

Table of Contents

 EXHIBIT 1.01(a) 
 FORMS OF ASSIGNMENT OF INTELLECTUAL PROPERTY 
 PATENT ASSIGNMENT 
 This PATENT ASSIGNMENT (this “Assignment”) is made and entered into this      day of
            , 2007 by and between Celsion Corporation, a Delaware corporation (“Assignor”), and Boston Scientific Corporation, a Delaware corporation
(“Assignee”) (each a “Party,” and collectively, the “Parties”). 
 WHEREAS, Assignor is
the owner of the patents and patent applications set forth on Schedule A hereto (the “Patents”); 
 WHEREAS, Assignor and
Assignee are parties to that certain Asset Purchase Agreement dated April 17, 2007 (the “Purchase Agreement”) (capitalized terms used herein but not otherwise defined herein shall have the meanings set forth in the Purchase
Agreement); 
 WHEREAS, pursuant to the Purchase Agreement, Assignee agreed to purchase the BPH Business from Assignor, including all of
Assignor’s right, title and interest in and to the Patents; and 
 WHEREAS, the execution and delivery of this Assignment is a condition
to Closing. 
 NOW THEREFORE, for the consideration set forth in the Purchase Agreement, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 1. Assignment. Effective upon the Closing,
Assignor hereby assigns to Assignee all of Assignor’s right, title and interest in and to the Patents, including all rights therein provided by international conventions and treaties, and the right to sue for past, present and future
infringement thereof. 
 2. No Warranties. Except as expressly provided in the Purchase Agreement, Assignor makes no warranties,
express or implied, with respect to the Patents. 
 3. Further Assurances. Assignor hereby covenants that Assignor shall, at the cost
and expense of Assignee, take all actions and execute all documents necessary or desirable to record and perfect the interest of Assignee in and to the Patents, and shall not enter into any agreement in conflict with this Assignment. 
  

 1 

Table of Contents

 IN WITNESS WHEREOF, each Party has caused this Assignment to be executed as of the date first written
above by its duly authorized officer. 
  

			
	ASSIGNOR
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	ASSIGNEE
		
	By:	 	  

	Name:	 	
	Title:	 	

  

 2 

Table of Contents

 SCHEDULE A 
  

									
	 Country
	 	 Application No.
	 	 Patent No.
	 	 Filing Date
	 	 Issue Date

  

 3 

Table of Contents

 TRADEMARK ASSIGNMENT 
 This TRADEMARK ASSIGNMENT (this “Assignment”) is made and entered into this      day of
            , 2007 by and between Celsion Corporation, a Delaware corporation (“Assignor”), and Boston Scientific Corporation, a Delaware corporation
(“Assignee”) (each a “Party,” and collectively, the “Parties”). 
 WHEREAS, Assignor is
the owner of the trademarks, trademark registrations and trademark applications set forth on Schedule A hereto (the “Trademarks”); 
 WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement dated April 17, 2007 (the “Purchase Agreement”) (capitalized terms used herein but not otherwise defined herein shall have the
meanings set forth in the Purchase Agreement); 
 WHEREAS, pursuant to the Purchase Agreement, Assignee agreed to purchase the BPH Business
from Assignor, including all of Assignor’s right, title and interest in and to the Trademarks and any and all goodwill of the business symbolized by the Trademarks; and 
 WHEREAS, the execution and delivery of this Assignment is a condition to Closing. 
 NOW THEREFORE, for the consideration set forth in the Purchase Agreement, and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties agree as follows: 
 1. Assignment. Effective upon the Closing, Assignor hereby assigns to
Assignee all of Assignor’s right, title and interest in and to the Trademarks and any and all goodwill of the business symbolized by the Trademarks, including all rights therein provided by international conventions and treaties, and the right
to sue for past, present and future infringement thereof. 
 2. No Warranties. Except as expressly provided in the Purchase Agreement,
Assignor makes no warranties, express or implied, with respect to the Trademarks. 
 3. Further Assurances. Assignor hereby covenants
that Assignor shall, at the cost and expense of Assignee, take all actions and execute all documents necessary or desirable to record and perfect the interest of Assignee in and to the Trademarks, and shall not enter into any agreement in conflict
with this Assignment. 
  

 1 

Table of Contents

 IN WITNESS WHEREOF, each Party has caused this Assignment to be executed as of the date first written
above by its duly authorized officer. 
  

			
	ASSIGNOR
		
	By:	 	  

	Name:	 	
	Title:	 	
		
	ASSIGNEE	 	
		
	By:	 	  

	Name:	 	
	Title:	 	

  

 2 

Table of Contents

 SCHEDULE A 
  

					
	 Mark
	 	 Application No.
	 	 Filing Date

  

 3 

Table of Contents

 COPYRIGHT ASSIGNMENT 
 This COPYRIGHT ASSIGNMENT (this “Assignment”) is made and entered into this      day of
            , 2007 by and between Celsion Corporation, a Delaware corporation (“Assignor”), and Boston Scientific Corporation, a Delaware corporation
(“Assignee”) (each a “Party,” and collectively, the “Parties”). 
 WHEREAS, Assignor is
the owner of the copyrights, copyright registrations and copyright applications set forth on Schedule A hereto (the “Copyrights”); 
 WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement dated April 17, 2007 (the “Purchase Agreement”) (capitalized terms used herein but not otherwise defined herein shall have the
meanings set forth in the Purchase Agreement); 
 WHEREAS, pursuant to the Purchase Agreement, Assignee agreed to purchase the BPH Business
from Assignor, including all of Assignor’s right, title and interest in and to the Copyrights; and 
 WHEREAS, the execution and
delivery of this Assignment is a condition to Closing. 
 NOW THEREFORE, for the consideration set forth in the Purchase Agreement, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 1.
Assignment. Effective upon the Closing, Assignor hereby assigns to Assignee all of Assignor’s right, title and interest in and to the Copyrights, including all rights therein provided by international conventions and treaties, and the
right to sue for past, present and future infringement thereof. 
 2. No Warranties. Except as expressly provided in the Purchase
Agreement, Assignor makes no warranties, express or implied, with respect to the Copyrights. 
 3. Further Assurances. Assignor hereby
covenants that Assignor shall, at the cost and expense of Assignee, take all actions and execute all documents necessary or desirable to record and perfect the interest of Assignee in and to the Copyrights, and shall not enter into any agreement in
conflict with this Assignment. 
  

 1 

Table of Contents

 IN WITNESS WHEREOF, each Party has caused this Assignment to be executed as of the date first written
above by its duly authorized officer. 
  

			
	ASSIGNOR
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	ASSIGNEE
		
	By:	 	  

	Name:	 	
	Title:	 	

  

 2 

Table of Contents

 SCHEDULE A 
  

					
	 Copyright
	 	 Application No.
	 	 Filing Date

  

 3 

Table of Contents

 EXHIBIT 1.01(b) 
 FORM OF ASSUMPTION AGREEMENT 
 ASSUMPTION AGREEMENT 
 ASSUMPTION AGREEMENT, dated as of                  , 2007
(this “Agreement”), by and between CELSION CORPORATION, a Delaware corporation (the “Seller”) and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Purchaser”). 
 WHEREAS, the Seller and the Purchaser have entered into an Asset Purchase Agreement, dated as of April 17, 2007 (the “Asset Purchase
Agreement”), providing, among other things, for the assumption by the Purchaser of certain liabilities of the Seller relating to the BPH Business; 
 WHEREAS, the execution and delivery of this Agreement is a condition to the Closing; 
 NOW, THEREFORE, in
consideration of the premises and the mutual agreements and covenants set forth herein and in the Asset Purchase Agreement, and intending to be legally bound hereby, the Purchaser and the Seller hereby agree as follows: 
 1. Definitions. All capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Asset Purchase
Agreement. 
 2. Assumption of Liabilities. Subject to Section 3 hereof, the Purchaser hereby assumes and agrees to pay, perform
and discharge when due the following and no other Liabilities of the Seller as of the date hereof (the “Assumed Liabilities”): 
 (i) all Liabilities with respect to, arising out of or relating to the ownership, possession or use of the BPH Assets or the operation of the BPH Business, in each case, by the Purchaser after the Closing Date,
including all Claims or Losses related in whole or in part to injuries and losses from products or services manufactured, produced, filled, packaged, marketed, sold or otherwise distributed by or on behalf of the Purchaser after the Closing Date;

 (ii) all Liabilities under all contracts, licenses (including Seller IP Agreements), sublicenses, agreements, leases,
commitments, and sales and purchase orders, and under all bids and offers, in each case, related to the BPH Business, transferred to the Purchaser and to the extent attributable to the period after the Closing Date (other than Liabilities or
obligations attributable to any failure by the Seller to comply with the terms thereof); 
 (iii) all Claims or Losses arising
out of or resulting from the breach of any representation or warranty, covenant or agreement by BSC contained in the Distribution Agreement or resulting from the performance by BSC of its obligations under Sections 2.02 and 2.05 of the Distribution
Agreement; and 

Table of Contents

 (iv) all Liabilities arising after the Closing Date relating to the employment by the
Purchaser of any employees of the Seller arising in the course of such employment. 
 3. Excluded Liabilities. Notwithstanding the
provisions of Section 2 hereof, the Seller shall retain, and shall be responsible for paying, performing and discharging when due, and the Purchaser shall not assume or have any responsibility for, all Liabilities of the Seller as of the date
hereof or at any time thereafter, other than the Assumed Liabilities (the “Excluded Liabilities”), including, without limitation: 
 (i) all Indebtedness of the Seller; 
 (ii) all Liabilities relating to employees of the
Seller, including all Liabilities under any of the Seller’s employee benefits agreements, plans or other arrangements; 
 (iii) all accounts payable and other accrued liabilities with respect to the BPH Business incurred on or prior to the Closing Date; 
 (iv) all Taxes now or hereafter owed by the Seller or any Affiliate of the Seller, or attributable to the BPH Assets or the BPH Business, relating to any period, or any portion of any period, ending on or
prior to the Closing Date; 
 (v) all Liabilities pursuant to Environmental Law arising from or related to any action, event,
circumstance or condition related to the BPH Business or the Real Property, in each case occurring or existing on or prior to the Closing Date; 
 (vi) all Claims or Losses related in whole or in part to injuries and losses from products or services manufactured, produced, filled, packaged, marketed, sold or otherwise distributed by or on behalf of the Seller on
or prior to the Closing Date; 
 (vii) all Liabilities arising out of any action, suit, proceeding or investigation pending or
threatened as of, or arising out of or relating to any event or condition occurring or existing on or prior to, the Closing Date; 
 (viii) all Liabilities under all contracts, licenses, sublicenses, agreements, leases, subleases, commitments, and sales and purchase orders, and under all bids and offers, in each case related to the BPH Business to the extent arising
on or prior to the Closing Date or otherwise attributable to any failure by the Seller to comply with the terms thereof; 
 (ix) all Liabilities relating to or arising out of the Excluded Assets; and 
 (x) all other Liabilities with respect
to, arising out of or relating to the ownership, possession or use of the BPH Assets or the operation of the BPH Business by the Seller or any Affiliate of the Seller prior to the Closing Date. 
  

 2 

Table of Contents

 4. Counterparts. This Agreement may be executed in one or more counterparts, and by the different
parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. 
 5. Assignment; Binding upon Successors and Assigns. Except as provided in this Section 5, neither the Seller nor the Purchaser may assign any
of its rights or obligations hereunder without the express written consent of the other party (which consent may be granted or withheld in the reasonable discretion of such party); provided that the Purchaser may assign its rights and
obligations under this Agreement without the approval of the Seller to an Affiliate of the Purchaser or to the purchaser of all or substantially all of the BPH Assets. In the event of such an assignment pursuant to the preceding sentence, the
assignee shall receive the benefit of this Agreement and shall succeed to all of the rights of the assigning party hereunder. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors, heirs,
legatees and permitted assigns. No assignment by either party permitted hereunder shall relieve the applicable party of its obligations under this Agreement. 
 6. No Rights in Third Parties. Nothing expressed or implied in this Agreement is intended to confer upon any person, other than the Purchaser and the Seller and their respective successors and assigns, any
rights, remedies, obligations or liabilities under or by reason of this Agreement. 
 7. Governing Law and Venue. This Agreement shall
be governed by, and construed in accordance with, the laws of the State of Delaware. The parties unconditionally and irrevocably agree and consent to the exclusive jurisdiction of the courts located in the State of Delaware and waive any objection
with respect thereto, for the purpose of any action, suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, and further agree not to commence any such action, suit or proceeding except in any such
court. 
 8. Further Action. Each of the parties hereto shall use reasonable best efforts to take, or cause to be taken, all
appropriate action, do or cause to be done all things necessary, proper or advisable under applicable Law, and execute and deliver such documents and other papers, as may be required to carry out the provisions of this Agreement and consummate and
make effective the transactions contemplated by this Agreement. 
  

 3 

Table of Contents

 IN WITNESS WHEREOF, the Purchaser and the Seller have caused this Agreement to be executed as of the date
first written above by their respective officers thereunto duly authorized. 
  

			
	 CELSION CORPORATION

		
	By	 	  

	Name:	 	
	Title:	 	
	
	BOSTON SCIENTIFIC CORPORATION
		
	By	 	  

	Name:	 	
	Title:	 	

  

 4 

Table of Contents

 EXHIBIT 1.01(c) 
 FORM OF BILL OF SALE AND ASSIGNMENT 
 BILL OF SALE AND ASSIGNMENT 
 BILL OF SALE AND ASSIGNMENT, dated as of                  ,
2007, from CELSION CORPORATION, a Delaware corporation (the “Seller”) to BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Purchaser”). 
 WHEREAS, the Seller and the Purchaser have entered into an Asset Purchase Agreement, dated as of April 17, 2007 (the “Asset Purchase
Agreement”), providing, among other things, for the sale to the Purchaser of certain assets of the Seller; and 
 WHEREAS, the
execution and delivery of this Bill of Sale and Assignment by the Seller is a condition to the Closing. 
 NOW, THEREFORE, for good and
valuable consideration, receipt of which is hereby acknowledged, and pursuant to the Asset Purchase Agreement, the Seller, intending to be legally bound, does hereby agree as follows: 
 1. Definitions. All capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Asset Purchase
Agreement. 
 2. Sale and Assignment of Assets. The Seller does hereby sell, assign, transfer, convey and deliver to the Purchaser,
and the Purchaser hereby purchases from the Seller, free and clear of all liens, claims, interests and Encumbrances (other than Permitted Encumbrances), all of the Seller’s right, title and interest in and to the following: 
 (i) the BPH Business as a going concern; 
 (ii) the goodwill of the Seller relating to the BPH Business; 
 (iii) all the Owned Real Property, if any, and all leasehold rights in respect of the Leased Real Property, if any; 
 (iv) all furniture, fixtures, equipment, machinery, vehicles and other tangible personal property primarily used in the conduct of the BPH
Business and not otherwise included in clause (iii) above; 
 (v) all Control Units, wherever located (including at
customer sites), owned by the Seller; 
 (vi) all Inventories; 
 (vii) all Receivables arising from the conduct of the BPH Business following the Closing Date; 
 (viii) all prepaid items, including any ad valorem Taxes, leases and rentals, related to the BPH Business; 

Table of Contents

 (ix) all books of account, general, financial, Tax and personnel records, invoices,
shipping records, supplier lists, correspondence and other documents, records and files and any rights thereto owned, associated with or employed by the Seller in connection with the BPH Business, including all correspondence records related to
the Product Approvals; 
 (x) all the Seller’s right, title and interest in, to and under the BPH Intellectual Property
and the Seller IP Agreements, copies and tangible embodiments thereof in whatever form or medium, and all rights to sue and recover damages, costs and attorney’s fees for past, present and future infringement, dilution, misappropriation,
violation, unlawful imitation or breach thereof; 
 (xi) all claims, causes of action, choses in action, rights of recovery
and rights of setoff of any kind (including rights to insurance proceeds and rights under and pursuant to all warranties, representations and guarantees made by suppliers of products, materials, or equipment, or components thereof) related to the
BPH Business pertaining to or inuring to the benefit of the Seller; provided, that, all damages, awards, payments and reimbursements of costs inuring to the benefit of the Seller (including all structured settlement or deferred payment
awards and rights to insurance proceeds) arising out of any Action commenced prior to the Closing shall be owned by the Seller, subject to (A) any rights, pursuant to the Distribution Agreement, of BSC or any other BSC Indemnified Party (as
such term is defined in the Distribution Agreement) and (B) any rights, pursuant to the Transaction Agreement, of BSC or any other BSC Indemnified Party (as such term is defined in the Transaction Agreement), in each case, in such Action;

 (xii) all manufacturing information, sales and promotional literature, lists of former and present suppliers and customers
and other sales-related materials related to the BPH Business, including the Products, owned, used, associated with or employed by the Seller at the Closing Date; 
 (xiii) all scientific, clinical, technical and other data related to the Products; 
 (xiv) all rights of the Seller under all contracts, licenses, sublicenses, agreements, leases, commitments, and sales and purchase orders,
and under all bids and offers (to the extent such offers are transferable), in each case, related to the BPH Business; 
 (xv) all permits, licenses, agreements, waivers, authorizations and approvals, including all Product Approvals, owned, held or used by the Seller in connection with, or required for, the BPH Business, to the extent transferable; and

 (xvi) all the Seller’s right, title and interest on the Closing Date in, to and under all other assets, rights,
claims, properties, goodwill and business of every kind and description and wherever located, whether tangible or intangible, real, personal or mixed, directly or indirectly owned by the Seller related to the BPH Business. 
  

 2 

Table of Contents

 3. Excluded Assets. Notwithstanding the provisions of Section 2 hereof, the BPH Assets shall
not include, and the Seller shall not sell, assign, transfer or deliver to the Purchaser, the Seller’s right, title and interest in and to the following: 
 (i) all Receivables arising from the conduct of the BPH Business on or prior to the Closing Date; 
 (ii) all insurance policies related to claims by the Seller for Losses arising on or prior to the Closing Date; 
 (iii) all refunds related to Taxes now or hereafter paid by the Seller or any Affiliate of the Seller, or attributable to the
BPH Assets or the BPH Business, relating to any period, or any portion of any period, ending on or prior to the Closing Date; 
 (iv) all minute and stock books of the Seller and any other documents relating to the organization, maintenance and existence of the Seller as a corporation; 
 (v) all damages, awards, payments and reimbursements of costs inuring to the benefit of the Seller (including all structured settlement or
deferred payment awards and rights to insurance proceeds) arising out of any Action commenced prior to the Closing, other than (A) any rights, pursuant to the Distribution Agreement, of BSC or any other BSC Indemnified Party (as such term is
defined in the Distribution Agreement) and (B) any rights, pursuant to the Transaction Agreement, of BSC or any other BSC Indemnified Party (as such term is defined in the Transaction Agreement), in each case, in such Action; and 
 (vi) all rights of the Seller under this Agreement and the Ancillary Agreements. 
 4. Further Assurances. The Seller hereby covenants and agrees that, at any time and from time to time after the date of this Bill of Sale and
Assignment, at the Purchaser’s request, the Seller will do, execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, any and all further acts, conveyances, transfers, assignments, and assurances as
necessary to grant, sell, convey, assign, transfer, set over to or vest in the Purchaser any of the BPH Assets. 
 5. Obligations and
Liabilities Not Assumed. The terms and provisions of the assumption of liabilities by the Purchaser are set forth in the Assumption Agreement dated as of the date hereof between the Purchaser and the Seller. Nothing expressed or implied in this
Bill of Sale and Assignment shall be deemed to be an assumption by the Purchaser of any liabilities of the Seller. The Purchaser does not by this Bill of Sale and Assignment assume or agree to pay, perform or discharge any liabilities of the Seller
of any nature, kind or description whatsoever. 
 6. Assignment; Binding upon Successors and Assigns. This Bill of Sale and Assignment
shall not be assigned by operation of Law or otherwise without the express written consent of the Seller and the Purchaser (which consent may be granted or withheld in the sole discretion of the Seller or the Purchaser); provided that the
Purchaser may assign its rights and 
  

 3 

Table of Contents

 
obligations under this Agreement without the approval of the Seller to an Affiliate of the Purchaser or to the purchaser of all or substantially all of the
BPH Assets. In the event of such an assignment pursuant to the preceding sentence, the assignee shall receive the benefit of this Bill of Sale and Assignment and shall succeed to all of the rights of the Purchaser hereunder. This Bill of Sale and
Assignment shall be binding upon and inure to the benefit of the parties hereto and their respective successors, heirs, legatees and permitted assigns. No assignment by either party permitted hereunder shall relieve the applicable party of its
obligations under this Bill of Sale and Assignment. 
 7. No Rights in Third Parties. Nothing expressed or implied in this Bill of
Sale and Assignment is intended to confer upon any person, other than the Purchaser and the Seller and their respective successors and permitted assigns, any rights, remedies, obligations or liabilities under or by reason of this Bill of Sale and
Assignment. 
 8. Severability. If any term or other provision of this Bill of Sale and Assignment is invalid, illegal or incapable of
being enforced by any Law or public policy, all other terms and provisions of this Bill of Sale and Assignment shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is
not affected in any manner materially adverse to either the Seller or the Purchaser. 
 9. Governing Law and Venue. This Agreement
shall be governed by, and construed in accordance with, the laws of the State of Delaware. The parties unconditionally and irrevocably agree and consent to the exclusive jurisdiction of the courts located in the State of Delaware and waive any
objection with respect thereto, for the purpose of any action, suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, and further agree not to commence any such action, suit or proceeding except in
any such court. 
  

 4 

Table of Contents

 IN WITNESS WHEREOF, this Bill of Sale and Assignment has been executed by the parties hereto as of the
date first above written. 
  

			
	 CELSION CORPORATION

		
	By:	 	  

	Name:	 	
	Title:	 	
	
	BOSTON SCIENTIFIC CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	

Table of Contents

 Exhibit 2.10 
 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). IT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE NOTE
UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION THAT REGISTRATION IS NOT REQUIRED. 
 FORM OF 
 CONVERTIBLE PROMISSORY NOTE 
  

			
	$[            ]	 	[            ], 200[  ]

 1. Promise to Repay. Celsion Corporation, a Delaware corporation (the
“Borrower”), promises to pay to Boston Scientific Corporation, a Delaware corporation (“Lender”; capitalized terms used but not defined herein have the meanings given to them in the Asset Purchase Agreement, dated
as of April 17, 2007, between Borrower and Lender (the “Asset Purchase Agreement”)), or its registered assigns, the principal sum of [            ] and
[            ]/100 Dollars ($[            ]) together with interest thereon at the rate hereinafter specified and
any and all other sums which may be due and owing to Lender in accordance with the terms contained herein as repayment of the $[            ] loan Lender has made to Borrower on the
date hereof in respect of Purchaser Amounts under Section 2.10 of the Asset Purchase Agreement. If the Purchaser Amounts ultimately actually paid by Lender to third parties are less than originally estimated by Purchaser in establishing the
initial principal amount of this Note, the principal amount of this Note shall be reduced on a dollar-for-dollar basis to reflect such reduced Purchaser Amounts effective as of the date such final Purchaser Amounts are calculable. 
 2. Interest. Borrower shall pay interest from the date of this Note on the principal amount outstanding from time to time at a rate per annum
equal to one percent (1%) above that rate of interest that The Bank of America publicly announces as, and declares to be, the regular commercial prime rate of interest of such bank that such bank uses as a guideline for, and a standard in
determining, actual interest rates charged commercial borrowers (the “Prime Rate”). Changes in the interest rate applicable in determining the interest due hereunder shall be made daily as of and immediately upon the occurrence of
changes in the Prime Rate. Notwithstanding any other provision contained in this Note, the maximum rate of interest hereunder at any time shall not exceed the maximum rate then permitted by law. The interest shall be due on the first to occur of
(i) the Maturity Date (as defined below), (ii) upon repayment of the Note in full or (iii) upon conversion of the principal amount plus accrued interest, if any, of the Note to shares of Borrower’s common stock, par value $.01
(the “Common Stock”), as provided in Section 6 below. 
 3. Calculation of Interest. Interest on the principal
amount of this Note shall be calculated on the basis of a 360 day per year factor applied to the actual days on which there exists an unpaid principal balance due under this Note. 

Table of Contents

 4. Maturity. The principal balance of this Note, together with all then unpaid and accrued
interest, shall be due and payable in full on the earlier to occur of (a) the consummation of a Change in Control Transaction, (b) five Business Days following the first date that the “net sales,” calculated in a manner
consistent with the calculation thereof for Borrower’s audited financial statements contained in its most recent Annual Report on Form 10-K, generated by Borrower and its Subsidiaries for the immediately preceding twelve-month period exceed $20
million, (c) three Business Days following the day on which Borrower or any of its Subsidiaries receives at least $20 million of proceeds from the sale of any equity securities or securities convertible into equity securities of Borrower or any
of its Subsidiaries, or (d) three Business Days following the occurrence of a default of the sort described in Section 9 (the earlier of such dates, the “Maturity Date”). 
 For purposes of this Note, “Change of Control Transaction” means: 
 (i) the sale, lease, exchange, conveyance, disposition or other transfer (in one transaction or a series of related transactions) of all
or substantially all of the assets of Borrower or any Subsidiary to any Person or group of related Persons for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (a “Group”), together with any
Affiliates thereof; 
 (ii) the consolidation or merger of Borrower or any Subsidiary with or into any Person as a result of
which the beneficial owners of the Capital Stock of Borrower or such Subsidiary immediately prior to such consolidation or merger cease to beneficially own, in the aggregate, 50% or more of the outstanding shares of Capital Stock of Borrower or such
Subsidiary as a result of such consolidation or merger; 
 (iii) any Person or Group, together with any Affiliates thereof
(other than the Permitted Holders) becoming the beneficial owner or owner of record (by way of merger, consolidation or other business combinations or by purchase in one transaction or a series of related transactions) of shares representing more
than 50% of the aggregate ordinary voting power represented by the issued and outstanding Capital Stock of Borrower; or 
 (iv) any Person or Group, together with any Affiliates or related Persons thereof, shall succeed in having a sufficient number of its nominees elected to the Board of Directors of Borrower such that such nominees, when added to any existing
director remaining on the Board of Directors of Borrower after such election who was a nominee of or is an Affiliate or related Person of such Person or Group, will constitute a majority of the Board of Directors of Borrower. 
 5. Prepayment. Borrower may prepay this Note, together with all then unpaid and accrued interest, in whole or in part at any time or from time to
time without penalty or additional interest; provided, however, that Borrower may not prepay any Conversion Amount (as defined below) that is the subject of a Conversion Notice (as defined below). Any amounts prepaid hereunder shall be
applied as provided in Section 7 below. 
  

 2 

Table of Contents

 6. Conversion. Lender may convert the principal balance plus accrued interest, if any, in whole or
in part, into shares of Common Stock, at its election at any time beginning (a) on the earlier of (x) the Business Day following the day on which the Company enters into a definitive agreement with respect to a Change in Control
Transaction and (y) the occurrence of a Change of Control Transaction, (b) five Business Days following the first date that the “net sales”, calculated in a manner consistent with the calculation thereof for Borrower’s
audited financial statements contained in its most recent Annual Report on Form 10-K, generated by Borrower and its Subsidiaries for the immediately preceding twelve-month period exceed $20 million, (c) three Business Days following the day on
which Borrower or any of its Subsidiaries receives at least $20 million of proceeds from the sale of any equity securities or securities convertible into equity securities of Borrower or any of its Subsidiaries, or (d) three Business Days
following the occurrence of a default of the sort described in Section 9 (the “Conversion”). The conversion price for this Note shall be (x) the average closing price per share of Common Stock on the American Stock
Exchange (or such other stock exchange, interdealer quotation system or other market as then may be the primary market for transaction in the Common Stock of Borrower) as reported on www.Bloomberg.com (or, if unavailable, as reported by
Reuters) for the fifteen consecutive trading days ending on the second trading day prior to the date on which Lender delivers the Conversion Notice or (y) if the Common Stock is not traded on the American Stock Exchange or any other stock
exchange, interdealer quotation system or other market, at a price per share to be mutually agreed upon by Borrower and Lender or, if Borrower and Lender are unable to agree, at a price per share indicative of the fair market value of a share of
Common Stock as determined by an independent investment bank selected by Lender and reasonably acceptable to Borrower (as applicable, the “Conversion Price”). 
 If Lender undertakes the Conversion, Lender shall notify Borrower of the Conversion (the “Conversion Notice”) including the amount of
the principal balance of the Note plus accrued interest up to, but not including, the Note Conversion Date (as defined below) to be converted. The effective date of the Conversion shall be the date of the Conversion Notice (the “Note
Conversion Date”). Any amounts so converted to shares of Common Stock of Borrower shall reduce on a dollar for dollar basis the outstanding principal balance and accrued interest, if any, of this Note. 
 On full conversion of the Note, Lender shall surrender this Note at Borrower’s principal executive office, or, if this Note has been lost, stolen,
destroyed or mutilated, then, in the case of loss, theft or destruction, Lender shall deliver an indemnity agreement reasonably satisfactory in form and substance to Borrower or, in the case of mutilation, Lender shall surrender and cancel this
Note. Any fractional shares to be issued upon the Conversion shall be rounded down to the nearest whole share, and Borrower shall pay to Lender a cash amount equal to such fractional share. On conversion, Lender will be entitled to any accrued but
unpaid interest on the converted principal amount of this Note which has not been converted into shares of Common Stock as described above through the Note Conversion Date. Borrower warrants that Common Stock issuable on the Conversion will, upon
Conversion, be validly issued, fully paid and non-assessable and free from all taxes, liens and charges in respect of the issue thereof. 
 7. Payments. Payments will be applied first to interest and then to principal. Payments of interest must be made in such coin or currency of the United States of America as at the time 

  

 3 

Table of Contents

 
of payment is legal tender of the payment of public and private debts. Payments received after 2:00 P.M. will be treated as being received on the next
banking day. If any interest is paid on this Note that is deemed to exceed the then legal maximum rate, that portion of the interest payment representing an amount in excess of the then legal maximum rate will be deemed a payment of principal and
applied to the principal balance of this Note. 
 8. Events of Default and Remedies. Any failure to make any payment due under this
Note when due or upon the failure to comply with any other terms and provisions of this Note shall be a default under this Note and shall entitle Lender to all of the rights and remedies specified herein or otherwise available under applicable law,
without notice, any right to cure, or obligation to make demand for payment. Upon a default, the entire unpaid principal balance of this Note, together with all accrued but unpaid interest and other sums due hereunder, shall immediately become due
and payable in full and Lender shall have the right to bring suit for such amount and to exercise any other remedies available. 
 9.
Negative Covenants. So long as any amount under this Note shall remain unpaid, and unless Borrower shall have otherwise obtained the prior written consent of Lender, Borrower will not, and will not permit any and all corporations,
partnerships, limited liability companies, joint ventures, associations and other entities controlled by Borrower directly or indirectly through one or more intermediaries (each a “Subsidiary”) to (a) declare or pay any
dividend or make any distribution on or in respect of shares of Capital Stock of Borrower or any Subsidiary or (b) purchase, redeem or otherwise acquire or retire for value any Capital Stock of Borrower or any Subsidiary or any warrants, rights
or options to purchase or acquire shares of any class of such Capital Stock of Borrower or any Subsidiary, except (i) as required pursuant to an instrument existing on the date of the Asset Purchase Agreement or (ii) to the extent that the
aggregate amount of funds used to effect any such purchase, redemption, other acquisition or retirement is equal to or less than the aggregate proceeds to Borrower or any of its Subsidiaries from the sale of any equity securities or securities
convertible into equity securities of Borrower or any of its Subsidiaries during the period between the date of this Note and the date of such event. 
 10. Costs of Collection. If at any time the Indebtedness evidenced by this Note is collected through legal proceedings or this Note is placed in the hands of an attorney or attorneys for collection, Borrower
hereby agrees to pay all costs and expenses (including reasonable attorneys’ fees) incurred by Lender in collecting or attempting to collect such indebtedness. 
 11. Governing Law. This Note and all actions arising out of or in connection with this Note shall be governed by and construed in accordance with the laws of the State of Delaware. 
 12. Confession of Judgment. Upon any default hereunder and to the extent permitted by law, Borrower authorizes any attorney admitted to practice
before any court of record in the United States on behalf of Borrower to confess judgment against Borrower in the full amount due under this Note, including outstanding principal, accrued and unpaid interest and all other sums due hereunder.
Borrower waives the benefit of any and every statute, ordinance or rule of court which may be lawfully waived conferring upon Borrower any right or privilege, stay of execution, or supplementary proceeding or other relief from the immediate
enforcement of a 

  

 4 

Table of Contents

 
judgment or related proceedings on a judgment. The authority granted herein shall not be exhausted by any one or more exercises or be extinguished by any
judgment entered and may be exercised on one or more occasions and in one or more jurisdictions. 
 13. No Waiver. The delay or
failure of Lender to exercise its rights hereunder shall not be deemed a waiver thereof. No waiver of any rights of Lender shall be effective unless in writing and signed by Lender and any waiver of any right shall not apply to any other right or to
such right in any subsequent event or circumstance not specifically included in such waiver. 
 14. Notices. Any notices or other
communication required hereunder shall be deemed properly given if delivered in person or if mailed by registered or certified mail, postage prepaid, return receipt requested to the parties at the following addresses: 
 if to Borrower, to: 
 Celsion Corporation

 10220-L Old Columbia Road 
 Columbia, Maryland 21046-1705 
 Attention: President and Chief Executive Officer 
 Facsimile No: (410) 290-5394 
 with a
copy to: 
 Venable LLP 
 Two
Hopkins Plaza, Suite 1800 
 Baltimore, Maryland 21201 
 Attention: Michael J. Baader, Esq. 
 Facsimile: (410) 244-7742 
 if to Lender: 
 Boston Scientific Corporation

 One Boston Scientific Place 
 Natick, MA 01760-1537 
 Attention: Lawrence C. Best 
 Facsimile No: (508) 650-8956 
 with a copy to: 
 Boston Scientific Corporation 
 One Boston
Scientific Place 
 Natick, MA 01760-1537 
 Attention: General Counsel 
 Facsimile No: (508) 650-8956 
 with a copy to: 
  

 5 

Table of Contents

 Shearman & Sterling LLP 
 599 Lexington Avenue 
 New York, NY 10022

 Attention: Clare O’Brien, Esq. 
 Facsimile No: (646) 848-8966 
  

 6 

Table of Contents

 IN WITNESS WHEREOF, Borrower has caused this Note to be executed on its behalf by its duly
authorized officer as of the day and year first above written. 
  

			
	CELSION CORPORATION,
	 a Delaware corporation

		
	 By
	 	  

	 Name:
	 	
	 Title:
	 	

  

 7 

Table of Contents

 EXHIBIT 5.09 
 FORM OF TRANSITION SERVICES AGREEMENT 
 TRANSITION SERVICES AGREEMENT 
 TRANSITION SERVICES AGREEMENT, dated as of
                         , 2007 (this “Agreement”), between CELSION CORPORATION, a Delaware
corporation (“Celsion”) and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (“BSC”). 
 W
I T N E S S E T H: 
 WHEREAS, Celsion and BSC have entered into an Asset
Purchase Agreement, dated as of April 17, 2007, (the “Purchase Agreement”; all capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Purchase Agreement), pursuant to which Celsion
agreed to sell to BSC and BSC agreed to purchase from Celsion, certain assets of Celsion, all as more particularly set forth in the Purchase Agreement; 
 WHEREAS, it is contemplated under Section 5.09 of the Agreement that Celsion will provide to BSC and its subsidiaries at a cost to BSC equal to Celsion’s fully allocated cost those services reasonably
necessary for the conduct of the Business during the transitional period following the date hereof, all as more particularly set forth herein; 
 WHEREAS, Celsion is willing to provide, or cause to be provided, such services to BSC on the terms and conditions set forth herein; 
 NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants hereinafter set forth, Celsion and BSC hereby agree as follows: 
 1. Provision of Transition Services; Reimbursement of Expenses. (a) Celsion agrees to provide, or cause to be provided (upon the written request of the BSC entity for which such services will be provided
identifying in reasonable detail the specifics of each Line Item of Service to be performed by Celsion) to BSC and its subsidiaries for a period ending on the 12 months anniversary of the date hereof, unless otherwise specified herein (the
“Term”), each line item of service set forth on Exhibit A hereto (each such item, a “Line Item of Service”, and, collectively, all services provided hereunder being the “Transition Services”).
Celsion shall provide, or cause to be provided, the Transition Services pursuant to this Agreement in a commercially reasonable manner consistent with the manner and level of care with which such services were previously conducted by or provided to
Celsion. During the Term, Celsion shall assist BSC in the transfer of responsibility for the Transition Services to BSC and BSC shall use all commercially reasonable efforts to assume the responsibility for the Transition Services as promptly as
practicable. Celsion’s obligation to deliver a Line Item of Service shall be conditional upon Celsion obtaining the consent, where necessary, of any relevant third party provider; provided, however, that if such consent cannot be
obtained, the parties shall use their respective reasonable efforts to arrange for alternative methods of delivering such Line Item of Service. 
 (b) Each BSC entity shall reimburse each Celsion entity promptly upon the receipt by that BSC entity of a reasonably detailed written invoice from the Celsion entity providing the particular Transition Services for each Line Item of Service
rendered hereunder. Each BSC entity shall reimburse the billing Celsion entity for Celsion’s fully allocated cost for 

Table of Contents

 
each Line Item of Service. All invoices sent by a Celsion entity hereunder shall be sent to the BSC entity for which a particular Line Item of Service has
been requested. Any payments pursuant to this Agreement shall be made in the currency of the billing Celsion entity, within thirty (30) days after the date of receipt by each BSC entity of Celsion’s invoice. Celsion reserves the right to
charge interest on any amount which has been due from any particular BSC entity for more than thirty (30) days, at a rate equal to the prime lending rate in the billing country plus 1% per annum, and to suspend performance under this
Agreement upon failure of any particular BSC entity to make three or more consecutive payments as to each BSC entity pursuant to this Agreement. BSC hereby guarantees the performance of all BSC entities. Celsion hereby guarantees the performance of
all Celsion entities. 
 (c) Subject to its obligations to make payments pursuant to this Agreement for services previously rendered, BSC, or
any appropriate BSC entity, may terminate any or all Line Items of Service, either in whole or in part, under this Agreement upon 30 business days’ written notice. 
 (d) With respect to a particular Line Item of Service, Celsion, or any appropriate Celsion entity, shall be responsible for selecting the employees who will perform any particular Line Item of Service and
administering such employees, i.e. setting such employees’ hours of work, establishing compensation structure, work load balancing, etc., subject to Section 1(a) of this Agreement. BSC, or any appropriate BSC entity, shall have the right
to assist Celsion, or any appropriate Celsion entity, in directing the employees assigned to perform specific Line Items of Service with respect to the substance of their work and for determining authorization levels governing each particular Line
Item of Service and funds that employees will have the right to commit to each Line Item of Service. 
 (e) For a period ending on the
earlier of (i) such date as BSC can independently manufacture three lots of the Product on a consistent reproducable basis and (ii) the 12 months anniversary of the date hereof (the “Assistance Term”), Celsion shall make
available to BSC, on a full-time basis, the personnel that are listed on Exhibit B attached hereto for the purposes of rendering Transition Services hereunder; provided, however, that if an employee has joint responsibilities with respect to the BPH
Business and non-BPH Business aspects of Celsion’s business, the amount of time such employee shall be committed to provide to BSC shall be mutually agreed upon by BSC and Celsion. Celsion’s obligation to BSC under this Section 1(e)
shall expire with respect to any personnel that are listed on Exhibit B on the earliest of: (i) the date on which such person resigns (or retires) from Celsion or is terminated by Celsion (which termination may only be for good cause, as
determined by Celsion in good faith); (ii) the point in time after which BSC no longer requires the services of such person and terminates such services on 30 days’ written notice to Celsion, and (iii) the expiration of the Assistance
Term. BSC shall pay Celsion for the services provided in this Section 1(e) in accordance with Section 1(b). 
 (f) Celsion shall,
and shall cause its employees to, observe and comply in all material respects with any and all Laws bearing on the performance of the Transition Services, including but not limited to (as applicable), the Occupational Safety & Health Act of
1970, as amended, the Fair Labor Standards Act of 1938, as amended, Title VII of the Civil Rights Acts of 1964 and 1991, the Age Discrimination in Employment Act, the Americans with Disability 

  

 2 

Table of Contents

 
Act and Executive Order 11246, as amended (including Equal Opportunity and Nondiscrimination provisions thereof), FIFRA and all Environmental Laws pertinent
to the performance of the Transition Services. 
 (g) Celsion shall maintain any facility, office or other space which is provided under this
Agreement in compliance in all material respects with all applicable Laws and regulations and in reasonable repair consistent with past practice, and shall maintain all material licenses and permits necessary or desirable with respect to such
properties. Celsion shall also maintain appropriate property, casualty and general liability insurance with respect to any such space occupied or shared by Celsion and BSC, including coverage for damage to or destruction of any personal property
located on such premises; provided, however, that BSC shall maintain personal property insurance with respect to its personal property. 
 (h) Celsion agrees to indemnify BSC and its Affiliates, officers, directors, employees, agents, successors and assigns for and hold them harmless from any liabilities, losses, damages, costs and expenses (including
reasonable attorney’s fees) incurred by them arising out of the provision by Celsion or any of its Affiliates of Transition Services, except where such liabilities, losses, damages, costs and expenses arise out of the gross negligence, willful
misconduct or bad faith of, or the violation of any Law by, any of such persons, or willful breach of any of BSC’s obligations under this Agreement. Notwithstanding the foregoing, in no event shall Celsion be liable to BSC for any
consequential, incidental or special damages suffered by BSC arising out of this Agreement. 
 2. Force Majeure. Subject to the last
sentence of this Section 2, any delay in the performance of any of the duties or obligations of either Celsion or BSC hereunder (except for payment obligations) shall not be considered a breach of this Agreement and the time required for
performance shall be extended for a period equal to the period of such delay, provided that such delay has been caused by or is the result of any of the following: acts of God; acts of the public enemy; insurrections; riots; embargoes; labor
disputes, such as strikes, lockouts or boycotts; fires; explosions; floods; earthquakes; and mud slides, provided that any of such events must be (a) beyond the reasonable control of the party declaring a force majeure event and (b) not
owing to the negligence or willful misconduct of the party declaring a force majeure event. The party declaring a force majeure event shall give prompt notice to the other party of such cause, and shall take whatever reasonable steps are necessary
to relieve the effect of such cause as rapidly as possible. If the force majeure event continues for a consecutive 90-day period, the delay in the performance of any of the duties or obligations of the party declaring the force majeure event shall
cease to be protected by this Section 2 and the other party may terminate this Agreement immediately upon notice to the party declaring the force majeure event. 
 3. Confidentiality. (a) Each of Celsion and BSC hereby acknowledges that such party’s Confidential Information may be exposed to the other parties’ employees and agents as a result of the
activities contemplated by this Agreement. During the term of this Agreement and for the period of five years thereafter, the Receiving Party shall maintain Confidential Information in confidence, and shall not disclose, divulge or otherwise
communicate such Confidential Information to others, or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement. The Receiving Party hereby shall exercise 
  

 3 

Table of Contents

 
every reasonable precaution to prevent and restrain the unauthorized disclosure of such Confidential Information by any of its directors, officers,
employees, consultants, subcontractors, or agents. Upon termination of this Agreement, Celsion and BSC hereby shall return to the other, upon demand, all Confidential Information in its possession or, upon demand, to destroy such Confidential
Information and provide a certificate to the other of such destruction. For the purposes of this Section 3, “Confidential Information” means all nonpublic proprietary information and materials (whether or not patentable),
disclosed by Celsion or BSC (the “Disclosing Party” to the other (the “Receiving Party”), irrespective of the manner in which the Disclosing Party disclosed such information, in furtherance of this Agreement.

 (b) The provisions of Section 3(a) shall not apply to any Confidential Information disclosed hereunder that: 
 (i) is lawfully disclosed to the Receiving Party by an independent, unaffiliated Person rightfully in possession of the Confidential
Information and under no confidentiality or fiduciary obligation not to make disclosure; 
 (ii) becomes published or
generally known to the public through no fault or omission on the part of the Receiving Party; 
 (iii) is developed
independently by the Receiving Party without access to the Confidential Information of the Disclosing Party; 
 (iv) a
Receiving Party is legally compelled to disclose; provided, however, that the Receiving Party shall provide prompt written notice of such requirement to the Disclosing Party so that the Disclosing Party may seek a protective order or
other remedy or waive compliance with Section 3(a); and provided further that in the event that such protective order or other remedy is not obtained or the Disclosing Party does not waive compliance with Section 3(a), the
Receiving Party shall be permitted to furnish only that portion of such Confidential Information that is legally required to be provided and the Receiving Party shall exercise its reasonable best efforts to obtain assurances that confidential
treatment shall be accorded such information. 
 4. Right to Audit. For a period of six (6) months after BSC receives an invoice
from Celsion for the provisions of Transition Services, BSC shall be provided, subject to the provision contained in Section 3 above, reasonable access to and the right to audit, at its cost and expense, by a mutually acceptable nationally
recognized accounting firm all of Celsion’s books and records principally relating to the provision of the Transition Services hereunder; provided, however, that neither BSC nor any agent of BSC shall have access to proprietary
technology of Celsion by virtue of this Section 4. 
 5. Notices. All notices, requests, claims, demands and other communications
hereunder shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by an internationally recognized overnight courier service, by telecopy or registered or certified
mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 5): 
  

 4 

Table of Contents

	 	(a)	if to Celsion: 

 Celsion Corporation 
 10220-I Old Columbia Road 
 Columbia,
Maryland 21046-1705 
 Attention: President and Chief Executive Officer 
 Facsimile No: (410) 290-5394 
 with a
copy to: 
 Venable, Baetjer and Howard, LLP 
 Two Hopkins Plaza, Suite 1800 
 Baltimore, Maryland 21201 
 Attention: Michael J. Baader, Esq. 
 Facsimile: (410) 244-7742 
  

	 	(b)	if to the Purchaser: 

 Boston Scientific Corporation

 One Boston Scientific Place 
 Natick, MA 01760-1537 
 Attention:
                             
 Facsimile No: (508) 650-8956 
 with a
copy to: 
 Boston Scientific Corporation 
 One Boston Scientific Place 
 Natick, MA 01760-1537 
 Attention: General Counsel 
 Facsimile No:
(508) 650-8956 
 6. Independent Contractor. Celsion shall act as an independent contractor and not as the agent of BSC in
performing the Transition Services, maintaining control over its employees, its subcontractors and their employees and complying with all withholding of income at source requirements, whether federal, state, local or foreign. No employee of Celsion
performing Transition Services shall be considered an employee of BSC or any of its affiliates until such time, if ever, as they accept BSC’s offer of employment. Furthermore, Celsion shall not subcontract any of the Transition Services without
the prior written approval of BSC; provided, however, that Celsion may subcontract the Transition Services to the extent subcontracted on the date hereof. Any such approval or subcontracting of the Transition Services shall not relieve
Celsion of its obligations under this Agreement. 
 7. Severability. If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect for so long as the economic or legal substance of the transactions contemplated
by this Agreement is not affected in any 
  

 5 

Table of Contents

 
manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the
parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated by this Agreement are consummated as
originally contemplated to the greatest extent possible. 
 8. Entire Agreement. This Agreement and the Purchase Agreement constitute
the entire agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede all prior agreements and undertakings, both written and oral, between the parties with respect to the subject matter hereof and thereof.

 9. Further Action. Each of the parties hereto shall use reasonable best efforts to take, or cause to be taken, all appropriate
action, do or cause to be done all things necessary, proper or advisable under applicable Law, and execute and deliver such documents and other papers, as may be required to carry out the provisions of this Agreement and consummate and make
effective the transactions contemplated by this Agreement. 
 10. Assignment. This Agreement shall be binding upon and inure to the
benefit of the parties hereto and their respective successors and permitted assigns. Neither party may assign this Agreement without the prior written consent of the other party, provided that BSC may assign its rights and obligations under
this Agreement without the approval of Celsion to an Affiliate of BSC or to the purchaser of all or substantially all of the BPH Assets. No assignment by either party permitted hereunder shall relieve the applicable party of its obligations under
this Agreement. 
 11. Amendment. This Agreement may not be amended or modified except (a) by an instrument in writing signed by,
or on behalf of, Celsion and BSC or (b) by a waiver in accordance with Section 15. 
 12. Governing Law and Venue. This
Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware. The parties unconditionally and irrevocably agree and consent to the exclusive jurisdiction of the courts located in the State of Delaware and waive
any objection with respect thereto, for the purpose of any action, suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, and further agree not to commence any such action, suit or proceeding except
in any such court. 
 13. Counterparts. This Agreement may be executed and delivered (including by facsimile transmission) in one or
more counterparts, and by the different parties in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart
of a signature page to this Agreement by facsimile shall be effective as delivery of a manually executed counterpart of this Agreement. 
 14. Specific Performance. The parties hereto acknowledge and agree that remedies at law would be an inadequate remedy for the breach of any agreement contained herein and that in addition thereto, the parties hereto shall be entitled
to specific performance of the terms hereof or other equitable remedies in the event of any such breach. 
  

 6 

Table of Contents

 15. Waiver. Either party to this Agreement may (a) extend the time for the performance of any
of the obligations or other acts of the other party, (b) waive any inaccuracies in the representations and warranties of the other party contained herein or in any document delivered by the other party pursuant hereto or (c) waive
compliance with any of the agreements of the other party or conditions to such party’s obligations contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the party to be bound
thereby. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Agreement. The failure of any party to
assert any of its rights hereunder shall not constitute a waiver of any of such rights. All rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available. 
 16. No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of the parties hereto and their permitted
assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever. 
  

 7 

Table of Contents

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first
written above by their respective officers thereunto duly authorized. 
  

			
	 CELSION CORPORATION

		
	By:	 	  

	Name:	 	
	Title:	 	
	
	BOSTON SCIENTIFIC CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	

  

 8 

Table of Contents

 EXHIBIT A 
 TRANSITION SERVICES 
  

	1.	Customer, Marketing and Supply Chain Activities 

  

	2.	Information Technology (I.T.) Support 

  

	3.	Regulatory Services 

  

	4.	Laboratory Services/Testing/Trials 

  

	5.	Office/Operational Space 

  

	6.	Miscellaneous 

 Any additional Transition Services,
reasonably requested by BSC, to the extent such services are necessary or appropriate for the conduct of the BPH Business by BSC and of a nature previously performed by Celsion for the BPH Business. 

Table of Contents

 EXHIBIT B 
 PERSONNELExhibit 10.2

 Exhibit 10.2 
 SECOND AMENDMENT 
 TO 
 TRANSACTION AGREEMENT 
 This SECOND AMENDMENT TO TRANSACTION AGREEMENT (this
“Amendment”) is entered into as of April 17, 2007 by and between CELSION CORPORATION, a Delaware corporation having its principal place of business at 10220-L Old Columbia Road, Columbia, Maryland 21046 (“Celsion”)
and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation having its principal place of business at One Boston Scientific Place, Natick, Massachusetts 01760 (“BSC”). All capitalized terms that are not otherwise defined herein shall
have the meanings assigned to them in the Original Transaction Agreement. 
 WHEREAS, Celsion and BSC entered into that certain Transaction
Agreement, dated as of January 20, 2003 (the “Original Transaction Agreement”), and the First Amendment to Transaction Agreement, dated as of August 8, 2005 (the “First Amendment” and together with the Original
Transaction Agreement and all exhibits and schedules thereto, the “Transaction Agreement”), and have agreed to revise certain terms of the Asset Purchase Agreement. 
 NOW, THEREFORE, in consideration of the premises and the mutual representations, agreements and covenants set forth herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Celsion and BSC hereby agree as follows: 
 ARTICLE I

 AMENDMENTS TO TRANSACTION AGREEMENT 
 SECTION 1.01 Amendments to Transaction Agreement. The Transaction Agreement is hereby amended as follows: 
 (a) The last sentence of SECTION 8.02(b) is hereby deleted and replaced with the following: 
 The Final
Option Notice shall be deemed to have been given upon the execution of the Asset Purchase Agreement by BSC and Celsion. 
 (b)
Exhibit D to the Original Transaction Agreement is hereby deleted and replaced with the form of Asset Purchase Agreement attached as Exhibit A hereto. 

 ARTICLE II 
 MISCELLANEOUS 
 SECTION 2.01 Entire Agreement. This Amendment sets forth the entire
agreement of the parties with respect to the subject matter of this Amendment and supersedes all previous understandings, written or oral, in respect of this Amendment. 
 SECTION 2.02 Continuing Effect of Transaction Agreement. Except as expressly amended hereby, all of the provisions of the Transaction Agreement are ratified and confirmed and remain in full force and effect. In
the event there are any conflicts between the terms of the Transaction Agreement and this Amendment, this Amendment shall control. 
 SECTION
2.03 One Agreement; References; Fax Signature. The Transaction Agreement, as amended by this Amendment, will be construed as one agreement. All references in any documents to the Transaction Agreement will be deemed to be references to the
Transaction Agreement as amended by this Amendment. This Amendment may be signed by facsimile signatures or other electronic delivery of an image file reflecting the execution hereof, and, if so signed: (i) may be relied on by each party as if the
document were a manually signed original and (ii) will be binding on each party for all purposes. 
 SECTION 2.04 Captions. The
headings to the Sections of this Amendment have been inserted for convenience of reference only and shall in no way modify or restrict any provisions hereof or be used to construe any such provisions. 
 SECTION 2.05 Counterparts. This Amendment may be executed in multiple counterparts, each of which, when executed and delivered, shall be an
original but all of which together shall constitute one and the same instrument. 
 SECTION 2.06 Governing Law. This Amendment shall
be governed by and construed in accordance with the internal laws of the State of Delaware. 
 SECTION 2.07 Waiver. Either party to
this Agreement may (a) extend the time for the performance of any of the obligations or other acts of the other party, (b) waive any inaccuracies in the representations and warranties of the other party contained herein or in any document delivered
by the other party pursuant hereto or (c) waive compliance with any of the agreements of the other party or conditions to such party’s obligations contained herein. Any such extension or waiver shall be valid only if set forth in an instrument
in writing signed by the party to be bound thereby. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of
this Agreement. The failure of any party to assert any of its rights hereunder shall not constitute a waiver of any of such rights. All rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies
otherwise available. 
 SECTION 2.08 No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the
benefit of the parties and their permitted assigns and 
  

 2 

 
nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature
whatsoever. 
 SECTION 2.09 Specific Performance. The parties hereto agree that irreparable damage would occur in the event any
provision of this Agreement was not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or equity. 
 SECTION 2.10 Agreement. All Schedules and Exhibits attached to this Agreement shall be deemed part of this Agreement and incorporated herein, as
if fully set forth herein. 
 [The remainder of this page has been left blank intentionally.] 
  

 3 

 IN WITNESS WHEREOF, Celsion and BSC have caused this Amendment to be executed as of the date first
written above by their respective officers thereunto duly authorized. 
  

			
	CELSION CORPORATION
		
	By:	 	 /s/ Michael H Tardugno

	Name:	 	Michael H Tardugno
	Title:	 	President and Chief Executive Officer
	
	BOSTON SCIENTIFIC CORPORATION
		
	By:	 	 /s/ Lawrence C. Best

	Name:	 	Lawrence C. Best
	Title:	 	 Executive Vice President-Finance and
 Administration
and Chief Financial Officer

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}]]